Werner Syndrome

🏷

Classifications

Harrison's Part

NIH Highlighted Topic

🔗

Mappings

MONDO

MONDO:0010196 Werner syndrome

Primary MONDO disease identifier for this Werner syndrome entry.

👪

Inheritance

1

Autosomal recessive HP:0000007

Classical WS is caused by homozygous or compound heterozygous loss-of-function variants in WRN. Virtually all WRN variants found in clinically ascertained patients are functional null alleles.

Autosomal recessive inheritance

Show evidence (3 references)

PMID:26993153 SUPPORT Other

"It is caused by null mutations of the WRN gene, which encodes a member of the RECQ family of DNA helicases."

Establishes WS as caused by null WRN alleles; the recessive mechanism requires both copies to be inactivated.

PMID:903377 SUPPORT In Vitro

"patients with Werner's syndrome (WS) of an autosomal recessive premature aging disease"

Independent statement that WS is autosomal recessive.

PMID:20301687 SUPPORT Other

"Werner syndrome is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a WRN pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being..."

States the inheritance mode together with the quantitative sib recurrence risks, which is what the mode means operationally for a family.

?

Discussions and Knowledge Gaps

6

Does the requirement for a telomerase-null background in the mouse mean that telomere attrition is the true rate-limiting step in human WS, or only that mice need their telomere advantage removed before any WRN-dependent phenotype can be seen?

HUMAN MODEL MISMATCH OPEN mismatch_wrn_mouse_telomere_reserve

Attached to

pathophysiology#Telomere Maintenance Failure pathophysiology#Segmental Progeroid Tissue Failure

Wrn-null mice with long telomeres are phenotypically normal, and a Werner-like syndrome appears only in late-generation mTerc-/- Wrn-/- animals. Two readings are compatible with this. Under the first, telomere attrition is genuinely the rate-limiting step and the mouse cross simply restores a human-like telomere baseline; the hTERT rescue of WS patient fibroblasts supports this. Under the second, the mouse has redundant RecQ or telomere-protection capacity that humans lack, and the telomerase-null background unmasks a phenotype whose human rate-limiting step is elsewhere — for instance in replication fork recovery at non-telomeric loci, which the mouse experiments did not assess. The two readings diverge on whether telomere-directed intervention would be disease-modifying in patients, so the distinction is not academic. Note also that the Wrn helicase-domain-deletion mouse has a mild phenotype and a 10-15% shorter median lifespan where the full null does not, raising the separate possibility of a dominant-negative contribution from helicase-dead protein that a pure loss-of-function model cannot capture.

Proposed experiments

Non-telomeric damage burden in hTERT-rescued WS fibroblasts

exp_ws_htert_nontelomeric_damage_burden

hTERT immortalization abolishes the proliferative defect of WS fibroblasts, but whether it also normalizes damage accumulation at non-telomeric DNA has not been assessed. Quantifying genome-wide damage foci, common fragile site expression and replication fork progression in matched WS and WS-hTERT fibroblasts would separate the two readings: full normalization supports telomeres as rate-limiting, while a persisting non-telomeric defect implies the mouse cross unmasks rather than reproduces the human mechanism.

Why is the WS neoplasm spectrum mesenchymally weighted rather than resembling the epithelial-dominated cancer spectrum of ordinary aging?

KNOWLEDGE GAP OPEN gap_ws_mesenchymal_tumor_spectrum

Attached to

pathophysiology#Cancer Predisposition with Mesenchymal Weighting

If WS were simply accelerated aging, its tumor spectrum should be a time-shifted version of the general-population spectrum. It is not: sarcomas, melanoma, meningioma and thyroid neoplasms dominate, with standardized incidence ratios up to 53.5-fold. Two non-exclusive explanations are current — differential WRN dependence across lineages and cell-turnover rates, and the preferential use by sarcomas of the recombination-based ALT telomere maintenance pathway that WRN normally suppresses. Neither has been tested in a way that would apportion the effect, and the discrepancy is a standing argument against reading WS as a general model of aging.

Do the vascular-stiffness and skin-ulcer signals from EMPOWER replicate in a larger parallel-group trial with washout-independent clinical endpoints?

KNOWLEDGE GAP OPEN gap_nr_empower_replication

Attached to

treatments#Nicotinamide Riboside (EMPOWER Early-Phase Trial) clinical_trials#jRCTs031190141

EMPOWER provides randomized, double-blind crossover evidence, but only nine participants were randomized and six completed. There was no washout, all three participants contributing ulcer measurements received NR first, the right ankle-brachial index worsened statistically, and prespecified metabolic, sarcopenia, blood-pressure, and kidney-function markers did not improve. A larger trial should prioritize durable ulcer healing, validated vascular and patient-reported endpoints, sufficient washout, and an analysis robust to dropout before NR is regarded as disease-modifying care.

Proposed experiments

Multicenter parallel-group NR replication trial

exp_ws_nr_parallel_replication

Randomize a multicenter molecularly confirmed WS cohort to NR or placebo with blinded ulcer adjudication, prespecified vascular endpoints, adequate follow-up, and pharmacodynamic NAD+ measurements.

Can genotype-restricted WRN-108 produce durable chronic-ulcer healing without unacceptable long-term on-target or off-target toxicity?

KNOWLEDGE GAP OPEN gap_wrn108_translational_model

Attached to

treatments#WRN-108 Genotype-Restricted Exon-Skipping ASO experimental_models#c.3139-1G>C Werner Fibroblast WRN-108 Rescue Model

WRN-108 restores an in-frame WRN transcript, partial protein expression, and nuclear localization in c.3139-1G>C patient fibroblasts. The animal work establishes dermal exposure and, in one primate, local exon skipping, but no model combines the human splice allele with a WS chronic-ulcer phenotype and no wound-healing efficacy endpoint was tested. The candidate is restricted to a defined splice-genotype subgroup; chronic dosing, wild-type transcript effects, and systemic safety remain unresolved.

Proposed experiments

Humanized c.3139-1G>C chronic-ulcer efficacy and safety study

exp_wrn108_humanized_ulcer_model

Test repeated dermal dosing in a model carrying the human target sequence and a reproducible WS-like wound phenotype, with healing, biodistribution, wild-type splice, immunogenicity, and long-term toxicology readouts.

Does macrophage RTE-dsRNA–DHX58–type-I-interferon signaling drive vascular disease in patient vessels and in vivo, beyond the iPSC co-culture system?

KNOWLEDGE GAP OPEN gap_rte_ifn_patient_vessel_validation

Attached to

pathophysiology#Retrotransposon-Derived dsRNA Accumulation in WS Macrophages pathophysiology#DHX58-Dependent Type I Interferon Inflammation experimental_models#Werner Syndrome iPSC-Derived Macrophage-Vascular Co-Culture

Patient, control, and gene-corrected iPSC-derived cells plus pathway silencing support a causal chain within the co-culture. Whether the same macrophage state exists in human arterial lesions, precedes clinical atherosclerosis, or can be inhibited without impairing host defense has not been established.

Proposed experiments

Spatial validation of RTE–IFN signaling in WS vessels

exp_ws_vessel_rte_ifn_validation

Combine spatial transcriptomics and dsRNA/IFN-pathway imaging in WS vascular tissue with lineage-resolved perturbation in an in vivo or vascular-organoid model.

How much of the longitudinal creatinine-based eGFR decline in WS represents renal injury rather than bias from low muscle mass and body-size indexing?

KNOWLEDGE GAP OPEN gap_ws_renal_trajectory_measurement

Attached to

phenotypes#Decreased Muscle Mass and Sarcopenic Physique treatments#Cancer Surveillance and Complication-Directed Management

The registry observed declining creatinine-based eGFR, but WS combines short stature, limb lipoatrophy, and sarcopenia, making creatinine production and body-surface-area normalization unusually problematic. Cystatin-C and unindexed estimates can disagree with standard eGFR; resolving the true renal trajectory matters for surveillance and drug dosing.

Proposed experiments

Longitudinal measured-GFR and body-composition cohort

exp_ws_measured_gfr_longitudinal

Compare measured GFR, creatinine, cystatin C, unindexed estimates, albuminuria, imaging, and quantitative muscle mass longitudinally in molecularly confirmed WS.

⚙

Pathophysiology

17

WRN Helicase-Exonuclease Loss of Function

Biallelic null variants in WRN abolish a 1,432-amino-acid nuclear protein that combines an ATP-dependent 3'->5' DNA helicase with an N-terminal 3'->5' exonuclease domain. The combination of the two catalytic activities in one polypeptide is unique among the five human RecQ helicases. Most disease alleles are stop codons, small indels or splice variants that truncate the protein and remove its C-terminal nuclear localization signal, so the residual product is excluded from the nucleus or degraded; the effect is loss of WRN function rather than a variant protein with altered activity.

WRN hgnc:12791

WRN 3'->5' DNA helicase activity GO:0003678 ⇓ LOSS OF FUNCTION WRN 3'->5' exonuclease activity GO:0008408 ⇓ LOSS OF FUNCTION

Downstream

Impaired WRN-Dependent Replication Progression Loss of nuclear WRN slows DNA-chain elongation and compromises handling of structured replication intermediates.

Telomere Maintenance Failure WRN is the RecQ helicase that resolves G-quadruplex and four-way-junction structures at telomeric repeats, so its loss acts directly on telomere replication.

NAD+ Depletion Patient samples and experimental models link WRN loss to reduced NMNAT1 expression and depletion of the NAD+ pool.

SHOX Promoter G-Quadruplex Persistence Loss of WRN helicase activity prevents efficient unwinding of a G-quadruplex in the SHOX promoter in stem-cell and zebrafish models.

Retrotransposon-Derived dsRNA Accumulation in WS Macrophages In a patient-derived iPSC model, WRN deficiency is associated with retrotransposon derepression and cytoplasmic double-stranded RNA.

Show evidence (3 references)

PMID:8602509 SUPPORT Human Clinical

"The predicted protein is 1432 amino acids in length and shows significant similarity to DNA helicases."

The original positional cloning study identifies the WS gene product as a putative DNA helicase of 1,432 residues.

PMID:8602509 SUPPORT Human Clinical

"One of the these mutations, which results in a frameshift and a predicted truncated protein"

Documents truncating WRN alleles as the disease mechanism, consistent with loss of function.

PMID:26993153 SUPPORT Other

"A unique feature of the WRN helicase is the presence of an exonuclease domain in its N-terminal region."

Establishes the dual helicase-exonuclease architecture that distinguishes WRN from the other human RecQ helicases.

c.3139-1G>C-Dependent WRN Pre-mRNA Missplicing

In the genotype-specific subgroup homozygous for WRN c.3139-1G>C, disruption of the intron-25 splice acceptor causes exon 26 skipping, a frameshift, and a premature stop in exon 27. This therapeutic vulnerability is not asserted for other WRN genotypes or for Werner syndrome generally.

WRN hgnc:12791

RNA splicing GO:0008380 ⚠ ABNORMAL

Downstream

WRN Helicase-Exonuclease Loss of Function Exon 26 skipping shifts the reading frame and introduces a premature stop, preventing production of functional nuclear WRN.

WRN-108-Directed Exon 27 Skipping Only when sequence-matched WRN-108 is administered, steric occupancy of exon 27 redirects splicing to an exon 25-exon 28 product.

Show evidence (1 reference)

PMID:42095135 SUPPORT In Vitro

"c.3139-1G>C, which leads to exon 26 skipping"

The patient genotype and its abnormal exon-26-skipping event define the restricted untreated RNA vulnerability.

WRN-108-Directed Exon 27 Skipping

In c.3139-1G>C-homozygous patient fibroblasts exposed to WRN-108, induced skipping of exon 27 joins exon 25 to exon 28 and restores the open reading frame. This is an investigational, treatment-conditioned state.

WRN hgnc:12791

RNA splicing GO:0008380

Experimental models

c.3139-1G>C Werner Fibroblast WRN-108 Rescue Model PRIMARY CELL CULTURE Measures the exon 25-exon 28 splice junction after WRN-108 exposure.

Downstream

Restored Partial WRN Expression and Nuclear Localization The in-frame exon 25-exon 28 transcript supports expression of a shortened WRN protein retaining the nuclear localization signal.

Show evidence (1 reference)

PMID:42095135 SUPPORT In Vitro

"subsequent DNA sequencing confirmed exon 25–28 junction formation"

Sequencing directly verifies the WRN-108-induced splice junction.

Restored Partial WRN Expression and Nuclear Localization

WRN-108-treated c.3139-1G>C patient fibroblasts re-express a shortened WRN protein that localizes to nuclei and partially restores genome-maintenance readouts. This preclinical molecular rescue does not establish wound healing or clinical benefit.

WRN hgnc:12791

Experimental models

c.3139-1G>C Werner Fibroblast WRN-108 Rescue Model PRIMARY CELL CULTURE Measures WRN protein abundance/localization and downstream genome-maintenance readouts.

Show evidence (1 reference)

PMID:42095135 SUPPORT In Vitro

"Treatment improved cell proliferation and reduced senescence-associated markers, G-quadruplex accumulation, and γH2AX signaling, consistent with partial restoration of WRN-dependent genome maintenance functions."

Patient-fibroblast functional readouts support partial rather than complete restoration of WRN-dependent cellular functions.

Impaired WRN-Dependent Replication Progression

WS fibroblasts show specifically slowed DNA-chain elongation while repair of X-ray-induced single-strand breaks and UV damage remains normal. This node therefore represents impaired replication progression and structured-DNA handling, not a global DNA-repair deficiency. More detailed fork intermediates have been proposed in newer cell studies, but are not asserted here without a directly cached primary source.

skin fibroblast CL:0002620

DNA replication GO:0006260 ↓ DECREASED

Downstream

Genomic Instability Persistently impaired replication progression contributes to accumulated chromosomal damage and rearrangement.

Accelerated Replicative Senescence Slowed replication and restricted replicative potential exhaust the proliferative capacity of WS cells.

Show evidence (3 references)

PMID:903377 SUPPORT In Vitro

"only the elongation rate of DNA chains, estimated by the molecular weight increase, was significantly slower during early passages in WS cells than in normal Hayflick Phase II fibroblasts"

Direct measurement showing that DNA chain elongation, not repair capacity, is the defective step in WS fibroblasts.

PMID:903377 SUPPORT In Vitro

"Five WS strains exhibited normal levels of sensitivity toward X-ray and UV killings and repair of X-ray induced single strand breaks of DNA (rejoining) and UV damage to DNA (unscheduled DNA synthesis)."

Negative result delimiting the defect: excision and single-strand break repair are intact, so this node should not be read as a global repair failure.

PMID:26993153 SUPPORT Other

"Biochemical and cell biological studies during the past decade have demonstrated involvements of the WRN protein in multiple DNA transactions, including DNA repair, recombination, replication and transcription."

Summarizes the DNA transactions supported by WRN, while the direct fibroblast experiment narrows this node to the demonstrated replication defect.

Telomere Maintenance Failure

Telomeric TTAGGG repeats form G-quadruplex structures that are preferred WRN substrates, and telomere replication requires resolution of four-way junctions at D- and T-loops. In the absence of WRN these structures can persist and telomere replication is impaired. Telomerase rescue in patient fibroblasts and the phenotype of late-generation Wrn-/- Terc-/- mice support telomere reserve as a rate-limiting model. They do not establish telomere attrition as the unique proximate trigger of the human multisystem phenotype.

telomere maintenance GO:0000723 ↓ DECREASED

Animal models

Telomere-limited Wrn-null mouse (mTerc-/- Wrn-/-) Mouse recapitulates Late-generation double-null mice demonstrate that telomere exhaustion can precipitate a Werner-like phenotype from Wrn loss in this engineered model.

Downstream

Accelerated Replicative Senescence Critically short, unprotected telomeres trigger a persistent DNA damage response and senescence.

Genomic Instability Uncapped telomeres promote chromosomal end fusions and telomere sister chromatid exchange.

Show evidence (3 references)

PMID:15235603 SUPPORT Model Organism

"we show that the varied and complex cellular phenotypes of Werner syndrome are precipitated by exhaustion of telomere reserves in mice"

Mouse genetics show that telomere exhaustion can precipitate a Werner-like phenotype in a sensitized double-null model; species and engineered-background limitations prevent direct assignment of human causal primacy.

PMID:15235603 SUPPORT In Vitro

"The capacity of enforced telomerase expression to rescue premature senescence of cultured cells from individuals with Werner syndrome"

Telomerase rescue places telomere reserve upstream of premature senescence in cultured WS fibroblasts, not necessarily upstream of every human feature.

PMID:26993153 SUPPORT Other

"A role of the WRN protein in telomere maintenance could explain many of the WS phenotypes."

The review explicitly frames telomere maintenance as an explanatory hypothesis ("could explain"), supporting calibrated rather than definitive language.

Genomic Instability

WS cells display "variegated translocation mosaicism" — multiple, variable, predominantly stable chromosomal rearrangements differing between clones — together with elevated telomere sister chromatid exchange and increased common fragile site expression. This is the mutator phenotype that underlies the WS cancer predisposition, and it is the shared feature that groups WS with the other RecQ disorders (Bloom syndrome, Rothmund-Thomson syndrome) as chromosomal instability syndromes.

DNA repair GO:0006281 ⚠ ABNORMAL

Downstream

Cancer Predisposition with Mesenchymal Weighting Accumulated chromosomal aberrations drive clonal evolution toward the characteristic WS neoplasm spectrum.

Show evidence (2 references)

PMID:23573208 SUPPORT Human Clinical

"Werner syndrome (WS) is an autosomal recessive genetic instability"

Systematic review characterizes WS as a genetic instability syndrome, the framing this node encodes.

PMID:15235603 SUPPORT Model Organism

"as well as increased chromosomal instability and cancer, particularly nonepithelial malignancies typical of Werner syndrome"

The telomere-depleted mouse model reproduces both the chromosomal instability and the nonepithelial (mesenchymal) tumor bias of human WS.

Accelerated Replicative Senescence

WS fibroblasts have a markedly restricted replicative lifespan and reduced plating efficiency relative to normal fibroblasts cultured in parallel, and accumulate DNA damage foci. Premature exhaustion of the proliferative reserve of mesenchymal and other renewable cell populations is the cellular event most directly connected to the progeroid tissue phenotypes. Enforced telomerase expression rescues premature senescence in cultured WS fibroblasts, while adipose and iPSC-derived models also implicate non-telomeric inflammatory programs; the relative contribution in patients is unresolved.

skin fibroblast CL:0002620

replicative senescence GO:0090399 ↑ INCREASED

Downstream

Segmental Progeroid Tissue Failure Loss of proliferative reserve in renewable tissues manifests as the accelerated-aging phenotypes of WS.

Senescence-Associated Adipogenic Failure In a primary adipose stromal-cell comparison, early senescence and a SASP accompany impaired adipogenesis and insulin signaling.

Show evidence (2 references)

PMID:903377 SUPPORT In Vitro

"plating efficiencies as well as the replicative potentials of five WS strains were more limited than those of normal cells under the identical culture conditions"

Directly measures the restricted replicative potential of WS fibroblasts against normal controls in the same culture conditions.

PMID:15235603 SUPPORT Model Organism

"This mouse model also showed accelerated replicative senescence and accumulation of DNA-damage foci in cultured cells"

Confirms accelerated replicative senescence and DNA damage focus accumulation in the telomere-limited Wrn-null model.

NAD+ Depletion

WS patient samples and invertebrate models show depletion of NAD+. WRN was reported to regulate transcription of NMNAT1, linking the nuclear WRN lesion to reduced NAD+ biosynthetic capacity. The degree and tissue distribution of this deficit in patients remain incompletely mapped.

Downstream

Impaired Mitophagy and Mitochondrial Quality Control Reduced NAD+ availability is associated with impaired mitophagy; NAD+ repletion improves mitochondrial quality through DCT-1- and ULK-1-dependent mitophagy in experimental models.

Show evidence (2 references)

PMID:31754102 SUPPORT Human Clinical

"Here we report impaired mitophagy and depletion of NAD+, a fundamental ubiquitous molecule, in WS patient samples and WS invertebrate models."

The human-sample clause supports NAD+ depletion in patient material; it is kept separate from the invertebrate-model arm of the same sentence.

PMID:31754102 SUPPORT Model Organism

"Here we report impaired mitophagy and depletion of NAD+, a fundamental ubiquitous molecule, in WS patient samples and WS invertebrate models."

The invertebrate-model clause supports the experimental organism arm and is not relabeled as human or in-vitro evidence.

Impaired Mitophagy and Mitochondrial Quality Control

Experimental WS systems show impaired clearance of dysfunctional mitochondria. NAD+ repletion improves mitochondrial quality through the mitophagy regulators DCT-1 and ULK-1 and extends lifespan in invertebrate WS models, but those organismal rescues are not human treatment evidence.

mitophagy GO:0000422 ↓ DECREASED

Show evidence (1 reference)

PMID:31754102 SUPPORT Model Organism

"NAD+ repletion restores NAD+ metabolic profiles and improves mitochondrial quality through DCT-1 and ULK-1-dependent mitophagy."

Genetic dependence on mitophagy regulators supports the quality-control mechanism in experimental WS systems.

SHOX Promoter G-Quadruplex Persistence

WRN helicase binds and unwinds a G-quadruplex in the SHOX promoter. WRN loss therefore leaves this regulatory structure unresolved in stem-cell and zebrafish systems, reducing SHOX transcription. This developmental model addresses the short-stature arm and is not a general explanation for adult progeroid manifestations.

Downstream

Reduced SHOX Transcription and Chondrogenesis Persistent promoter G-quadruplex structure reduces SHOX transcription and impairs chondrocyte differentiation.

Show evidence (1 reference)

PMID:36114168 SUPPORT In Vitro

"We identify short-stature homeobox (SHOX) as a crucial and direct target of WRN and find that the WRN helicase core regulates the transcriptional expression of SHOX via unwinding G-quadruplexes."

Stem-cell and molecular assays identify the WRN-SHOX promoter interaction and the G-quadruplex-unwinding step.

Reduced SHOX Transcription and Chondrogenesis

WRN-null hESC/hMSC differentiation and zebrafish models have reduced SHOX, impaired chondrogenesis, and short body length. SHOX overexpression rescues the developmental defect in both systems, placing SHOX downstream of WRN for this phenotype.

Downstream

Short Stature Reduced SHOX-dependent chondrogenesis directly models the absent pubertal growth spurt and short body length.

Show evidence (2 references)

PMID:36114168 SUPPORT In Vitro

"genetic overexpression of SHOX or shox expression rescues the bone developmental deficiency induced in WRN/wrn-null mutants both in vitro and in vivo."

The in-vitro arm supports SHOX rescue during stem-cell differentiation and is kept distinct from the zebrafish result.

PMID:36114168 SUPPORT Model Organism

"genetic overexpression of SHOX or shox expression rescues the bone developmental deficiency induced in WRN/wrn-null mutants both in vitro and in vivo."

The in-vivo zebrafish arm supports organismal rescue and is kept distinct from the cell-culture evidence.

Retrotransposon-Derived dsRNA Accumulation in WS Macrophages

In WS iPSC-derived macrophages, reduced H3K9me3 is associated with retrotransposable-element derepression and cytoplasmic double-stranded RNA. This is a model-specific vascular-inflammatory mechanism and has not been demonstrated as a systemic causal intermediate in patients.

Experimental models

Werner Syndrome iPSC-Derived Macrophage-Vascular Co-Culture CO CULTURE RNA-seq, ATAC-seq, chromatin profiling, and gene correction assay the retrotransposon/RNA-sensing arm in WS macrophages.

Downstream

DHX58-Dependent Type I Interferon Inflammation Retrotransposon-derived double-stranded RNA engages the DHX58-dependent cytoplasmic RNA-sensing pathway.

Show evidence (1 reference)

PMID:38858384 SUPPORT In Vitro

"H3K9me3 inversely correlates with RTEs, activating the DHX58-dependent RNA sensing pathway."

Multi-omic and perturbation data in patient-derived macrophages support the RTE-to-DHX58 sensing step.

DHX58-Dependent Type I Interferon Inflammation

RNA sensing in WS iPSC-derived macrophages drives type I interferon signaling, senescence, and inflammatory effects on co-cultured endothelial and vascular smooth-muscle cells. Interferon silencing reverses cellular readouts, but the experiment is a non-animal model rather than a clinical intervention.

Experimental models

Werner Syndrome iPSC-Derived Macrophage-Vascular Co-Culture CO CULTURE Interferon silencing and vascular co-culture assay the causal inflammatory step and its endothelial/smooth-muscle consequences.

Downstream

Premature Atherosclerosis This provisional, model-extrapolated edge places the macrophage inflammatory state upstream of endothelial dysfunction and smooth-muscle switching in a two-dimensional co-culture; it does not establish lesion formation in patients.

Show evidence (1 reference)

PMID:38858384 SUPPORT In Vitro

"Silencing type I IFN signaling rescues proliferation and suppresses senescence and inflammation, suggesting atherosclerosis treatment in WS."

Pathway silencing supplies intervention evidence for the modeled IFN-driven senescence and inflammation, without establishing patient efficacy.

Senescence-Associated Adipogenic Failure

Adipose stromal vascular fraction from one person with WS showed premature senescence, increased SASP genes, suppressed adipogenesis, and impaired insulin signaling relative to one healthy donor. Four-patient imaging and clamp data associated subcutaneous fat loss with insulin resistance. The cellular comparison is informative but very small.

Downstream

Loss of Subcutaneous Adipose Tissue in Limbs The patient-cell and imaging study directly connects failed adipogenesis with loss of the subcutaneous fat compartment.

Show evidence (2 references)

PMID:37793000 SUPPORT In Vitro

"Adipose-derived stem cells from the stromal vascular fraction derived from WS subcutaneous adipose tissues (WSVF) showed early replicative senescence and a significant increase in the expression of senescence-associated secretory phenotype (SASP) markers."

The primary-cell comparison directly connects early senescence and SASP to the affected adipose compartment.

PMID:37793000 SUPPORT Human Clinical

"Clinical data from four Japanese patients with WS revealed significant associations between the decrease of areas of subcutaneous fat and increased insulin resistance measured by the glucose clamp."

The small human series links the adipose phenotype to insulin resistance; it does not estimate population frequency.

Segmental Progeroid Tissue Failure

The organismal phenotype is segmental rather than global: some age-related changes are strikingly accelerated (cataract, hair graying and loss, skin atrophy, osteoporosis, atherosclerosis, type 2 diabetes) while others characteristic of normal aging are absent — Alzheimer-type dementia and increased amyloid deposition are not features, and the osteoporosis is worse in distal limb bones than in the vertebral column, the reverse of ordinary aging. The segmental pattern is a substantive constraint on the "accelerated aging" framing and should not be smoothed over: WS is not normal aging run fast.

Animal models

Telomere-limited Wrn-null mouse (mTerc-/- Wrn-/-) Mouse recapitulates The double-null mice develop premature death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts.

Wrn-null mouse on a telomerase-proficient background Mouse fails to recapitulate Wrn deficiency alone does not produce a Werner-like syndrome in mice with long telomeres.

Downstream

Bilateral Cataracts

Premature Graying and Thinning of Hair

Alopecia

Type 2 Diabetes Mellitus

Osteoporosis

Show evidence (2 references)

PMID:26993153 SUPPORT Other

"Werner syndrome (WS) is a prototypical segmental progeroid syndrome characterized by multiple features consistent with accelerated aging."

Establishes the segmental progeroid framing that this node encodes.

PMID:15235603 SUPPORT Model Organism

"telomere dysfunction elicits a classical Werner-like premature aging syndrome typified by premature death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts"

Enumerates the specific organismal features recapitulated when telomere reserves are exhausted in a Wrn-null background.

Cancer Predisposition with Mesenchymal Weighting

WS confers a strong, type-specific predisposition to a narrow set of neoplasms rather than a general increase in cancer. Six tumor types — thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcoma, leukemia and pre-leukemic marrow conditions, and primary bone neoplasms — account for about two-thirds of all reported neoplasms in WS patients, and the standardized incidence ratios in Japan-resident patients are elevated for all of these except leukemia. The mesenchymal and neural-crest weighting is the mechanistically informative part: it is the opposite of the epithelial-dominated spectrum of ordinary aging. The lineage bias remains mechanistically unresolved and should not be attributed to a specific telomere-maintenance pathway without direct evidence.

Downstream

Neoplasm

Thyroid Carcinoma

Malignant Melanoma

Soft Tissue Sarcoma

Meningioma

Osteosarcoma Osteosarcoma is retained as a narrower, registry-documented member of the broader primary-bone-neoplasm spectrum.

Show evidence (2 references)

PMID:23573208 SUPPORT Human Clinical

"The most frequent neoplasms in WS patients, representing 2/3 of all reports, were thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcomas, leukemia and pre-leukemic conditions of the bone marrow, and primary bone neoplasms."

Defines the WS neoplasm spectrum from a study population of 189 patients with 248 neoplasms.

PMID:23573208 SUPPORT Human Clinical

"Cancer risk defined by SIRs was significantly elevated in Japan-resident WS patients for the six most frequent neoplasms except leukemia"

Quantifies the risk elevation and records the leukemia exception, which this node preserves rather than generalizing away.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

27

Cardiovascular 3

Hypertension HP:0000822

Show evidence (1 reference)

PMID:33373317 SUPPORT Human Clinical

"Calcium antagonists and angiotensin-II receptor blockers were often used for patients with hypertension."

Supports the existence and management of hypertension in the registry but does not establish a population-frequency band.

Premature Atherosclerosis HP:0002621

Sequelae: Myocardial Infarction

Show evidence (2 references)

PMID:26993153 SUPPORT Other

"These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."

Lists atherosclerosis among the accelerated age-related disorders of WS.

PMID:33373317 SUPPORT Human Clinical

"A small percentage of patients had a history of atherosclerosis, such as cerebral infarction (0%), angina pectoris or myocardial infarction (2.5%), or arteriosclerosis obliterans (ASO) (15.0%) (Table 2)."

Directly quantifies the peripheral-arterial component as an occasional manifestation without assigning that value to all forms of atherosclerosis.

Myocardial Infarction HP:0001658

Show evidence (1 reference)

PMID:26993153 SUPPORT Other

"The most common causes of death are cancer and myocardial infarction, at a median age of 54"

Establishes myocardial infarction as a leading cause of death and gives the median age at death.

Digestive 1

Hepatic Steatosis FREQUENT HP:0001397

Show evidence (1 reference)

PMID:33373317 SUPPORT Human Clinical

"Over half of the patients had diabetes, impaired glucose tolerance (67.5%), dyslipidemia (65.0%), and fatty liver (52.5%)."

The modern registry directly supports the FREQUENT band.

Endocrine 3

Type 2 Diabetes Mellitus Type II diabetes mellitus HP:0005978

Onset: YOUNG ADULT

Show evidence (2 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places type 2 diabetes mellitus in the subsequent group occurring in the 30s; YOUNG_ADULT records that broad onset category without inferring a narrower age.

PMID:26993153 SUPPORT Other

"These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."

Directly identifies type 2 diabetes as a WS manifestation without treating the registry's combined diabetes/impaired-glucose-tolerance percentage as a type-2-diabetes-specific frequency.

Hypogonadism HP:0000135

Onset: YOUNG ADULT

Show evidence (2 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places hypogonadism in the subsequent group occurring in the 30s; YOUNG_ADULT records that broad onset category without inferring a narrower age.

PMID:26993153 SUPPORT Other

"These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."

Lists hypogonadism among the middle-age age-related disorders of WS.

Thyroid Carcinoma HP:0002890

Show evidence (1 reference)

PMID:23573208 SUPPORT Human Clinical

"ranging from 53.5-fold for melanoma of the skin (95% CI: 24.5, 101.6) to 8.9 (95% CI: 4.9, 15.0) for thyroid neoplasms"

Gives the standardized incidence ratio for thyroid neoplasms in Japan-resident WS patients.

Integument 3

Prematurely Aged Appearance VERY_FREQUENT HP:0007495

Show evidence (1 reference)

PMID:20301687 SUPPORT Other

"Werner syndrome is characterized by the premature appearance of features associated with normal aging and cancer predisposition."

GeneReviews opens its clinical description with the premature appearance of aging features, the disease-level claim this phenotype records.

Alopecia HP:0001596

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:7712642 SUPPORT Other

"thinning and graying of hair or baldness, nail dystrophy or loss, wrinkling and aging of the face"

Lists baldness among the dermatologic presentations of WS.

Intractable Lower Extremity Ulcers FREQUENT Skin ulcer HP:0200042

Onset: YOUNG ADULT

Show evidence (4 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places skin ulcers in the subsequent group occurring in the 30s; YOUNG_ADULT records that broad onset category without inferring a narrower age.

PMID:7712642 SUPPORT Other

"A dermatologist may be consulted because of the scleroderma-like appearance of the skin, lower-extremity ulcers or calluses"

Records lower-extremity ulceration as one of the dermatologic presentations that brings WS patients to clinical attention.

PMID:33373317 SUPPORT Human Clinical

"the percentage of patients with intractable skin ulcers had decreased (87.5% vs. 67.5%,P<0.01)"

The current-registry value of 67.5% supports the FREQUENT band.

+ 1 more reference

Metabolism 1

Dyslipidemia FREQUENT Abnormal circulating lipid concentration HP:0003119

Show evidence (1 reference)

PMID:33373317 SUPPORT Human Clinical

"Over half of the patients had diabetes, impaired glucose tolerance (67.5%), dyslipidemia (65.0%), and fatty liver (52.5%)."

The modern registry directly supports the FREQUENT band.

Musculoskeletal 2

Osteoporosis HP:0000939

Onset: YOUNG ADULT

Show evidence (2 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places osteoporosis in the subsequent group occurring in the 30s; YOUNG_ADULT records that broad onset category without inferring a narrower age.

PMID:26993153 SUPPORT Other

"These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."

Lists osteoporosis among the accelerated age-related disorders of WS.

Osteosarcoma HP:0002669

Show evidence (1 reference)

PMID:33373317 SUPPORT Human Clinical

"comprised lung cancer, lung adenocarcinoma, undifferentiated pleomorphic sarcoma, fibrosarcoma, osteosarcoma, colorectal cancer, follicular thyroid cancer, and melanoma."

The modern registry explicitly names osteosarcoma, so the HPO mapping and cited entity now have matching scope.

Growth 2

Truncal and Visceral Adiposity Truncal obesity HP:0001956

Show evidence (2 references)

PMID:26993153 SUPPORT Other

"thin limbs, truncal obesity, and flat feet."

Directly identifies truncal obesity as part of the characteristic body-fat distribution.

PMID:37130431 SUPPORT Human Clinical

"Patients with Werner syndrome tended to have sarcopenia obesity (visceral fat increase despite low BMI)."

The current registry supplies the modern visceral-fat/low-BMI context.

Short Stature VERY_FREQUENT HP:0004322

Onset: JUVENILE

Show evidence (3 references)

PMID:20301687 SUPPORT Other

"The first sign is the lack of a growth spurt during the early teen years."

Directly supports adolescent growth-spurt failure as the origin and first sign of short stature. JUVENILE records the early-teen category without inferring minimum or maximum ages.

PMID:7712642 SUPPORT Other

"The disease generally becomes apparent around puberty, with growth arrest"

Peripubertal growth arrest is the origin of the short stature in WS.

PMID:26993153 SUPPORT Other

"Cardinal signs include bilateral cataracts (present in 99% of WS cases), premature graying and/or thinning of scalp hair (100%), characteristic dermatologic changes (96%) and short stature (95%)"

Dedicated frequency evidence for the VERY_FREQUENT band on this phenotype: all four cardinal signs are reported at 95-100% in the WS registry cohort.

Neoplasm 3

Neoplasm OCCASIONAL HP:0002664

Show evidence (2 references)

PMID:33373317 SUPPORT Human Clinical

"Malignant tumor was observed in 20.0% of patients"

The n=40 registry places aggregate neoplasm burden in the OCCASIONAL band.

PMID:37130431 SUPPORT Human Clinical

"Malignant neoplasms were observed from the fifth decade of life (mean onset: 49.7 years) and were observed in approximately 30% of patients during the 3-year survey period."

The 51-person longitudinal registry supplies timing and an updated burden estimate near the upper boundary of the OCCASIONAL band.

Soft Tissue Sarcoma HP:0030448

Show evidence (1 reference)

PMID:23573208 SUPPORT Human Clinical

"thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcomas, leukemia and pre-leukemic conditions of the bone marrow, and primary bone neoplasms"

Places soft tissue sarcoma among the six defining neoplasms of the WS spectrum.

Meningioma HP:0002858

Show evidence (1 reference)

PMID:23573208 SUPPORT Human Clinical

"thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcomas, leukemia and pre-leukemic conditions of the bone marrow, and primary bone neoplasms"

Places meningioma among the six defining neoplasms of the WS spectrum.

Other 9

Bilateral Cataracts VERY_FREQUENT Posterior subcapsular cataract HP:0007787

Onset: YOUNG ADULT

Show evidence (5 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places bilateral ocular cataracts in the subsequent group occurring in the 30s; YOUNG_ADULT records that broad onset category without inferring a narrower age.

PMID:7712642 SUPPORT Other

"Rapidly progressing bilateral cataracts typically occur when patients are in their 20s and 30s."

Establishes bilateral cataracts with third-decade onset as a cardinal WS feature.

PMID:26993153 SUPPORT Other

"The cataracts seen in WS are almost always posterior sub-capsular, in contrast to those seen in normal aged people, which are typically nuclear cataracts."

Directly supports the posterior subcapsular localization represented by HP:0007787 and preserves the source's exact hyphenation.

+ 2 more references

Premature Graying and Thinning of Hair VERY_FREQUENT Premature graying of hair HP:0002216

Onset: YOUNG ADULT

Show evidence (3 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places premature graying and thinning among findings usually observed in the 20s; YOUNG_ADULT records that broad onset category without inferring a narrower age.

PMID:7712642 SUPPORT Other

"The disease generally becomes apparent around puberty, with growth arrest and thinning and graying of hair."

Documents peripubertal onset of hair graying and thinning as a presenting feature.

PMID:26993153 SUPPORT Other

"Cardinal signs include bilateral cataracts (present in 99% of WS cases), premature graying and/or thinning of scalp hair (100%), characteristic dermatologic changes (96%) and short stature (95%)"

Dedicated frequency evidence for the VERY_FREQUENT band on this phenotype: all four cardinal signs are reported at 95-100% in the WS registry cohort.

Scleroderma-like Skin Changes VERY_FREQUENT

Onset: YOUNG ADULT

Show evidence (3 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places scleroderma-like skin changes among findings usually observed in the 20s; YOUNG_ADULT records that broad onset category without inferring a narrower age.

PMID:7712642 SUPPORT Other

"A dermatologist may be consulted because of the scleroderma-like appearance of the skin"

Confirms scleroderma-like skin change as a presenting dermatologic feature of WS.

PMID:26993153 SUPPORT Other

"Cardinal signs include bilateral cataracts (present in 99% of WS cases), premature graying and/or thinning of scalp hair (100%), characteristic dermatologic changes (96%) and short stature (95%)"

Dedicated frequency evidence for the VERY_FREQUENT band on this phenotype: all four cardinal signs are reported at 95-100% in the WS registry cohort.

Soft-Tissue Calcification VERY_FREQUENT Ectopic calcification HP:0010766

Show evidence (1 reference)

PMID:33373317 SUPPORT Human Clinical

"that of soft-tissue calcification had increased (76.7% vs. 87.5%,P=0.048)"

The current-registry value of 87.5% supports the VERY_FREQUENT band.

Loss of Subcutaneous Adipose Tissue in Limbs FREQUENT HP:0003635

Show evidence (2 references)

PMID:26993153 SUPPORT Other

"Other features frequently seen in WS include a high pitched hoarse voice (recognizable over the phone), characteristic facial features (a “pinched” facial appearance), thin limbs, truncal obesity, and flat feet."

The clinical synthesis directly lists thin limbs among frequent WS features.

PMID:37793000 SUPPORT Human Clinical

"Clinical data from four Japanese patients with WS revealed significant associations between the decrease of areas of subcutaneous fat and increased insulin resistance measured by the glucose clamp."

Small human imaging/clamp data support the metabolic relevance of the lipoatrophy, but not its population frequency.

Bird-Like Facies VERY_FREQUENT HP:0000320

Show evidence (1 reference)

PMID:33373317 SUPPORT Human Clinical

"Approximately 90% of patients had a characteristic bird-like face and high-pitched voice."

The n=40 registry directly places the facial gestalt in the VERY_FREQUENT band.

Abnormally High-Pitched Voice VERY_FREQUENT HP:0001620

Onset: YOUNG ADULT

Show evidence (2 references)

PMID:20301687 SUPPORT Other

"Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."

GeneReviews places the characteristic vocal change, described there as hoarseness, among findings usually observed in the 20s. YOUNG_ADULT records that broad timing without conflating hoarseness with the mapped high-pitched-voice phenotype or inferring a narrower age.

PMID:33373317 SUPPORT Human Clinical

"Approximately 90% of patients had a characteristic bird-like face and high-pitched voice."

Directly supports the high-pitched-voice phenotype and its frequency band.

Decreased Muscle Mass and Sarcopenic Physique FREQUENT HP:0003199

Show evidence (2 references)

PMID:33373317 SUPPORT Human Clinical

"Therefore, in this registry, most patients aged over 40 years had sarcopenia."

Supports a frequent sarcopenic phenotype specifically among patients older than 40 years, not an all-ages penetrance estimate.

PMID:37130431 SUPPORT Human Clinical

"The grip strength and SMI met the diagnostic criteria for sarcopenia."

The 51-person registry independently supports low muscle mass and strength.

Malignant Melanoma HP:0002861

Show evidence (1 reference)

PMID:23573208 SUPPORT Human Clinical

"ranging from 53.5-fold for melanoma of the skin (95% CI: 24.5, 101.6)"

Quantifies melanoma as the most strongly elevated neoplasm risk in WS.

🧬

Genetic Associations

1

WRN (Causative)

Gene: WRN hgnc:12791

Autosomal recessive

Show evidence (4 references)

PMID:8602509 SUPPORT Human Clinical

"The gene responsible for WS (known as WRN) was identified by positional cloning."

Establishes WRN as the causal gene for Werner syndrome.

PMID:8602509 SUPPORT Human Clinical

"Four mutations in WS patients were identified. Two of the mutations are splice-junction mutations"

Documents the truncating/splicing character of the founding WRN disease alleles.

PMID:26993153 SUPPORT Other

"It is caused by null mutations of the WRN gene, which encodes a member of the RECQ family of DNA helicases."

Confirms that WS-associated WRN alleles act as functional nulls.

+ 1 more reference

🗃️

External Assertions

1

OMIM Werner syndrome

OMIM disease record OMIM:277700

OMIM phenotype entry for Werner syndrome, the WRN-related adult-onset progeroid syndrome.

💊

Medical Actions

7

Nicotinamide Riboside (EMPOWER Early-Phase Trial)

Action: Pharmacotherapy NCIT:C15986

Oral nicotinamide riboside (NR) 1000 mg daily was evaluated in a phase I/II double-blind randomized crossover study (26 weeks per arm). Eleven patients enrolled, nine were randomized, and six completed. No serious adverse events were reported during NR treatment; CAVI and ulcer-area signals favored NR. Interpretation is limited by the single-center sample, dropouts, no washout, and ulcer analysis in only three patients (all received NR first). Right ABI worsened statistically, and blood pressure, sarcopenia, lipid, glucose, and kidney-function markers did not differ significantly. NR is therefore an investigational option with early human evidence, not established disease-modifying care.

Mechanism Target:

RESTORES NAD+ Depletion — NR supplementation increased plasma NAD+ in the human crossover trial.

Show evidence (1 reference)

PMID:40459998 SUPPORT Human Clinical

"As expected, NAD+ levels increased significantly following NR treatment"

The pharmacodynamic measurement directly supports restoration of the depleted NAD+ pool, without proving correction of WRN itself.

Target Phenotypes: Skin ulcer HP:0200042 Atherosclerosis HP:0002621

Show evidence (3 references)

PMID:40459998 SUPPORT Human Clinical

"No serious adverse events were observed during NR treatment. Importantly, CAVI improved, the skin ulcer area decreased, and heel pad thinning showed a declining trend."

The randomized crossover report supplies the main safety and secondary endpoint signals.

PMID:40459998 SUPPORT Human Clinical

"No significant differences were observed between the NR and placebo phases in regard to changes from baseline regarding blood pressure; sarcopenia indicators, lipid metabolism parameters, glucose metabolism markers, and kidney function markers."

Negative secondary endpoints prevent a broad efficacy or renal-protection claim.

PMID:40459998 SUPPORT Human Clinical

"This study had some limitations. First, the number of patients was small because this was a single‐center study, which coincided with the COVID‐19 pandemic."

The authors' limitation statement supports cautious interpretation.

WRN-108 Genotype-Restricted Exon-Skipping ASO

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

WRN-108 is a fully phosphorothioate, uniformly 2'-MOE splice-switching ASO designed for the c.3139-1G>C subgroup. In patient fibroblasts it induces exon 27 skipping after pathogenic exon 26 skipping, restores an in-frame transcript, and re-establishes partial WRN protein expression and nuclear localization. Rat wounds established dermal pharmacokinetics; one cynomolgus monkey showed skin target engagement, and short mouse/minipig studies addressed tolerability. No model combined the human splice genotype with a WS chronic-ulcer phenotype, no wound-healing efficacy endpoint was tested, and long-term safety is unknown. Wild-type exon 27 skipping could reduce WRN expression. This is a genotype-restricted preclinical candidate, not clinical care.

Mechanism Target:

BYPASSES c.3139-1G>C-Dependent WRN Pre-mRNA Missplicing — WRN-108 causes additional exon 27 skipping to restore the open reading frame disrupted by c.3139-1G>C-dependent exon 26 skipping.

Show evidence (1 reference)

PMID:42095135 SUPPORT In Vitro

"subsequent DNA sequencing confirmed exon 25–28 junction formation"

The induced junction directly demonstrates bypass of the pathogenic frameshift-producing splice state.

Target Phenotypes: Skin ulcer HP:0200042

Show evidence (2 references)

PMID:42095135 SUPPORT In Vitro

"In WS patient-derived fibroblasts, WRN-108 efficiently induced exon 27 skipping, restored WRN protein expression, and re-established its nuclear localization."

Direct patient-cell evidence establishes the intended molecular effect.

PMID:42095135 SUPPORT Model Organism

"Although this evaluation was limited to a single animal, the detection of exon-skipped transcripts supports pharmacodynamic activity within treated tissue."

The single primate establishes local target engagement only, not efficacy or general safety.

Bosentan for Lower-Extremity Ulcers

Action: Pharmacotherapy NCIT:C15986

Agent: bosentan CHEBI:51450

Bosentan is a dual endothelin-receptor antagonist used for refractory lower-extremity ulcers in WS. GeneReviews recommends it on the basis of very limited disease-specific evidence, including case-level experience, rather than a controlled WS trial. It treats a manifestation, not the WRN defect, and should not be presented as established ulcer-healing efficacy.

Show evidence (1 reference)

PMID:20301687 SUPPORT Other

"Targeted therapy: Bosentan reduces vasoconstriction to improve healing of lower-extremity ulcers."

GeneReviews lists bosentan as the targeted therapy for WS lower-extremity ulcers and states its vasodilatory mechanism.

Genetic Counseling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

WS is autosomal recessive, so counseling of an affected proband's family turns on sib recurrence risk and on the testing options that molecular confirmation unlocks. Because sibs of a proband are themselves at 25% risk and WS is diagnosed late, GeneReviews additionally recommends evaluating apparently asymptomatic older and younger sibs, so that surveillance and preventive measures start before manifestations accumulate.

Show evidence (2 references)

PMID:20301687 SUPPORT Other

"each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier"

Gives the autosomal recessive recurrence risks that are the substance of counseling for this disorder.

PMID:20301687 SUPPORT Other

"Evaluate apparently asymptomatic older and younger sibs of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures."

Supports the at-risk-relative evaluation recommendation, which is counseling-initiated rather than proband-directed care.

Risk-Factor Avoidance

Action: behavioral counseling Ontology label: Behavioral Counseling NCIT:C181743

Avoidance recommendations in WS are not generic lifestyle advice: they are targeted at the specific acquired diseases that kill WS patients or cause the signature morbidity. Smoking and obesity are avoided for atherosclerosis (myocardial infarction being one of the two leading causes of death); smoking and alcohol for osteoporosis and cataracts, both of which arrive decades early; and falls, extremity trauma and excessive sun exposure because extremity trauma can worsen vulnerable skin and chronic ulcers.

Show evidence (1 reference)

PMID:20301687 SUPPORT Other

"Avoid smoking and obesity, which increase the risk for atherosclerosis. Avoid smoking and alcohol, which increase the risk of osteoporosis and cataracts. Avoid falls, trauma to the extremities, and excessive sun exposure."

States the agents and circumstances to avoid, each tied to the WS complication it accelerates.

Cataract Surgery

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Extraction of the bilateral posterior subcapsular cataracts, typically required around age 31. It is the single most consistently needed intervention in WS.

Show evidence (1 reference)

PMID:26993153 SUPPORT Other

"Bilateral cataracts requiring surgery are seen in virtually all cases by the late 20s or early 30s"

Establishes cataract surgery as a near-universal requirement in WS.

Cancer Surveillance and Complication-Directed Management

Action: supportive care Ontology label: Supportive Care NCIT:C15747

There is no curative or disease-modifying therapy. Management consists of treating manifestations, preventing secondary complications, and screening for the acquired diseases common in WS — in practice, surveillance weighted toward the six neoplasms that dominate the WS spectrum. Cancer treatment should be individualized with close hematologic and renal monitoring rather than a categorical, unsupported claim that every cytotoxic regimen requires modification. Creatinine-based kidney indices can be biased by small body size and sarcopenia, so BSA-uncorrected eGFR or cystatin-C estimates may be important for drug dosing.

Show evidence (5 references)

PMID:7712642 SUPPORT Other

"Patients should have a thorough clinical and laboratory work-up, keeping in mind their elevated risk for neoplasms."

Supports neoplasm-directed surveillance as the core of WS clinical management.

PMID:20301687 SUPPORT Other

"Annual surveillance includes ophthalmologic examination for cataracts; dual-energy x-ray absorptiometry to assess bone density; assessment for signs/symptoms of hypogonadism; fasting glucose level, hemoglobin A1c, or oral glucose tolerance test"

Specifies the annual surveillance schedule, which is broader than the neoplasm-directed work-up and is keyed to the WS complication set.

PMID:20301687 SUPPORT Other

"skin examination for ulcers and lentiginous melanoma; ten-year atherosclerotic cardiovascular disease risk estimation, lipid profile, blood pressure, lifestyle counseling, and assessment for cardiovascular risk factors"

Completes the annual schedule with the dermatologic and cardiovascular arms, the latter matching myocardial infarction as a leading cause of death in WS.

+ 2 more references

🔬

Diagnosis

2

Clinical Diagnostic Criteria (Four Cardinal Signs)

International Registry criteria classify a presentation as definite when all four cardinal signs — bilateral ocular cataracts, premature graying and/or thinning of scalp hair, characteristic dermatologic pathology, and short stature — occur with at least two additional signs. These historical clinical criteria are useful for recognition but do not replace molecular confirmation, especially before cataracts appear.

clinical evaluation NCIT:C124351

Results: Definite clinical criteria: all four cardinal signs plus at least two additional signs.

Show evidence (1 reference)

PMID:20301687 SUPPORT Other

"The diagnosis of Werner syndrome can be established in a proband with clinical diagnostic criteria (presence of all four cardinal signs: bilateral ocular cataracts, premature graying and/or thinning of scalp hair, characteristic dermatologic pathology, and short stature; and two additional..."

States the clinical criteria verbatim, including the requirement for two additional signs beyond the four cardinal ones.

WRN Molecular Genetic Testing

Identification of biallelic WRN pathogenic variants establishes the diagnosis independently of the clinical criteria. This matters more than a confirmatory test usually does in WS, because the clinical criteria are conjunctive and late-completing: a proband who has not yet developed cataracts cannot meet them, while the genotype is available from birth. It is also what makes the atypical, non-WRN progeroid presentations separable from WS proper. Sequence analysis should be followed by deletion/duplication or genome-scale analysis when needed. Biallelic variants of uncertain significance, or one pathogenic/likely pathogenic variant plus a VUS, do not establish the diagnosis.

molecular genetic testing NCIT:C15709

Markers: Biallelic WRN pathogenic variants

Results: Biallelic WRN pathogenic variants establish the diagnosis; identification in the proband also enables carrier testing of relatives and prenatal or preimplantation genetic testing. If a compelling phenotype yields only one pathogenic coding allele, targeted long-read or genome sequencing can detect deep-intronic and structural second alleles missed by routine analysis.

Show evidence (4 references)

PMID:20301687 SUPPORT Other

"or biallelic WRN pathogenic variants identified by molecular genetic testing"

States molecular confirmation as an alternative, independently sufficient route to the diagnosis.

PMID:20301687 SUPPORT Other

"Once the WRN pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible."

Supports the downstream family-testing options that follow from molecular confirmation in the proband.

PMID:35534204 SUPPORT Human Clinical

"The International Registry of Werner Syndrome has identified biallelic pathogenic variants in 179/188 cases of classical WS. In the remaining nine cases, only one heterozygous pathogenic variant has been identified."

Defines the high-yield unresolved scenario: a classic phenotype with one detected pathogenic WRN allele.

+ 1 more reference

📊

Prevalence

1

Japan

Carrier Frequency 602.4096386 per 100,000 >1 in 1,000

Estimated Japanese heterozygote frequency is about 1 in 166 (0.6024%, or 602.4 carriers per 100,000). This is a carrier-frequency estimate, not the prevalence of affected individuals.

Show evidence (1 reference)

PMID:26993153 SUPPORT Other

"In the Japanese population, the heterozygote frequency is estimated to be 1/166"

Directly supplies the 1-in-166 carrier estimate used for the structured percentage, rate per 100,000, and ABOVE_1_IN_1000 band.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Werner Syndrome:

Atypical Werner Syndrome Not Yet Curated MONDO:0019321

Overlapping Features Atypical Werner syndrome is a WRN-negative, genetically heterogeneous progeroid presentation rather than a subtype of classic Werner syndrome. Dominant LMNA and POLD1 variants are established causes within this residual clinical category.

Distinguishing Features

Absence of biallelic pathogenic WRN variants argues against classic Werner syndrome.
LMNA- and POLD1-associated atypical presentations are generally dominant, unlike autosomal recessive WRN disease.
POLD1-related MDPL may include mandibular hypoplasia, deafness, progeroid features, and lipodystrophy.

Show evidence (2 references)

PMID:26993153 SUPPORT Other

"These patients were suspected to have WS on clinical grounds, but were found on subsequent analysis to lack WRN mutations."

Directly supports separating the WRN-negative clinical mimic from classic biallelic-WRN Werner syndrome.

PMID:26993153 SUPPORT Other

"The POLD1 mutations found in AWS are dominant heterozygous mutations, p.Ser605del and p.Arg507Cys, which perturb polymerase activity"

Supplies a genetically distinct dominant cause within the atypical Werner category.

Hutchinson-Gilford Progeria Syndrome MONDO:0008310

Overlapping Features HGPS overlaps through alopecia, sclerodermatous skin, lipoatrophy, and severe atherosclerosis, but begins in childhood and is usually caused by a de novo LMNA cryptic-splice variant producing progerin. Classic WS is adolescent/adult onset, autosomal recessive, and WRN-related, with bilateral cataracts and its distinctive tumor spectrum.

Distinguishing Features

Childhood onset and failure to thrive favor HGPS over adult-onset Werner syndrome.
A de novo LMNA exon 11 cryptic-splice variant and progerin distinguish HGPS from biallelic WRN loss.
Bilateral posterior subcapsular cataracts and cancer predisposition favor Werner syndrome.

Show evidence (1 reference)

PMID:12714972 SUPPORT Human Clinical

"18 out of 20 classical cases of HGPS harboured an identical de novo (that is, newly arisen and not inherited) single-base substitution, G608G(GGC > GGT), within exon 11."

The primary human genetic series supplies the de novo LMNA mechanism that separates HGPS from inherited WRN disease.

Bloom Syndrome MONDO:0008876

Overlapping Features Bloom syndrome is another autosomal recessive RecQ-helicase cancer-predisposition disorder, but severe pre- and postnatal growth deficiency, photosensitivity, immune abnormalities, recurrent infections, and biallelic BLM variants distinguish it from adolescent-onset WS.

Distinguishing Features

Severe prenatal growth deficiency and photosensitive facial erythema favor Bloom syndrome.
Immune deficiency and recurrent infections are characteristic of Bloom syndrome, not classic Werner syndrome.
Biallelic BLM variants and markedly increased sister-chromatid exchange distinguish Bloom syndrome molecularly.

Show evidence (1 reference)

PMID:20301572 SUPPORT Other

"Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."

GeneReviews directly states the early growth, immune, photosensitivity, metabolic, and cancer pattern used to distinguish Bloom syndrome.

Rothmund-Thomson Syndrome MONDO:0010002

Overlapping Features Rothmund-Thomson syndrome overlaps through sparse hair, small stature, cataracts, and cancer predisposition. Its infantile poikiloderma, congenital skeletal abnormalities, and biallelic RECQL4 or ANAPC1 variants distinguish it from adult-onset WRN disease.

Distinguishing Features

A facial rash beginning at three to six months and evolving to poikiloderma strongly favors Rothmund-Thomson syndrome.
Radial-ray or other congenital skeletal abnormalities favor Rothmund-Thomson syndrome.
Biallelic RECQL4 or ANAPC1 variants distinguish RTS from biallelic WRN-related Werner syndrome.

Show evidence (1 reference)

PMID:20301415 SUPPORT Other

"The rash of RTS typically develops between ages three and six months (occasionally as late as age two years) as erythema, swelling, and blistering on the face, subsequently spreading to the buttocks and extremities."

The infantile rash timing sharply separates RTS from the post-pubertal onset of Werner syndrome.

📊

Related Datasets

1

Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model geo:GSE247722

GEO superseries for the WS iPSC-derived macrophage/endothelial/vascular smooth-muscle study, integrating RNA-seq, ATAC-seq, and chromatin profiling across patient, healthy-control, and gene-corrected cells.

human MULTI OMICS n=97

Conditions: Werner syndrome iPSC-derived macrophages and vascular cells healthy controls gene-corrected Werner syndrome controls

PMID:38858384

Identified by GEO discovery and verified against NCBI E-utilities on 2026-08-24; GEO reports Homo sapiens, 97 samples, and PMID:38858384.

Show evidence (1 reference)

PMID:38858384 SUPPORT In Vitro

"RNA-sequencing (seq) and assay for transposase-accessible chromatin using sequencing (ATAC-seq) reveal accelerated type I IFN signaling and reduced chromatin accessibility in WS-iMφs."

The publication describes the core omics assays represented by the superseries.

🔬

Clinical Trials

1

jRCTs031190141 PHASE_II COMPLETED

EMPOWER was a combined phase I/II, double-blind, randomized, placebo-controlled crossover trial of oral nicotinamide riboside 1000 mg daily for 26 weeks per arm in Werner syndrome. The registry target was 30; eleven enrolled, nine were randomized, and six completed in the publication. The schema lacks a combined phase-I/II value, so PHASE_II records the later phase while this description preserves the registry's exact phase 1-2 designation.

Target Phenotypes: Skin ulcer HP:0200042 Atherosclerosis HP:0002621

Show evidence (4 references)

ICTRP:JPRN-jRCTs031190141 SUPPORT Other

"| Study design | randomized controlled trial, double blind, placebo control, crossover assignment, treatment purpose |"

The sanctioned WHO ICTRP cache supplies the structured trial design.

ICTRP:JPRN-jRCTs031190141 SUPPORT Other

"| Recruitment status | Complete |"

The registry record establishes completed status.

ICTRP:JPRN-jRCTs031190141 SUPPORT Other

"| Phase | 1-2 |"

Preserves the registry's combined phase designation despite the local single-value phase enum.

+ 1 more reference

🧫

Experimental Models

2

Werner Syndrome iPSC-Derived Macrophage-Vascular Co-Culture CO_CULTURE

Two-dimensional co-culture of macrophages, vascular endothelial cells, and vascular smooth-muscle cells differentiated from healthy, WS, and gene-corrected WS iPSCs. The isogenic correction and cross-co-cultures localize the inflammatory driver to WS macrophages. The system models cell-cell interactions but lacks blood flow, vessel architecture, systemic immunity, and longitudinal plaque development.

Organism

human NCBITaxon:9606

Cell source

Patient-derived and healthy-control iPSCs, plus CRISPR-corrected WS iPSCs

Culture

Two-dimensional macrophage-endothelial and macrophage-smooth-muscle co-culture

Publication

PMID:38858384

Pathograph links

Retrotransposon-Derived dsRNA Accumulation in WS Macrophages RNA-seq, ATAC-seq, chromatin profiling, and gene correction assay the retrotransposon/RNA-sensing arm in WS macrophages.

Show evidence (1 reference)

PMID:38858384 SUPPORT In Vitro

"RNA-sequencing (seq) and assay for transposase-accessible chromatin using sequencing (ATAC-seq) reveal accelerated type I IFN signaling and reduced chromatin accessibility in WS-iMφs."

Multi-omic profiling directly supports the modeled macrophage state.

DHX58-Dependent Type I Interferon Inflammation Interferon silencing and vascular co-culture assay the causal inflammatory step and its endothelial/smooth-muscle consequences.

Show evidence (1 reference)

PMID:38858384 SUPPORT In Vitro

"Silencing type I IFN signaling rescues proliferation and suppresses senescence and inflammation, suggesting atherosclerosis treatment in WS."

Pathway perturbation supports the causal role in this model while not implying clinical treatment efficacy.

Show evidence (1 reference)

PMID:38858384 SUPPORT In Vitro

"In this work, we generate, characterize, validate, and use immune and vascular cells differentiated from iPSCs from healthy individuals and WS patients, as well as gene-corrected iPSCs from WS patients, and establish an in vitro model to better understand the atherosclerosis microenvironment at..."

Defines the patient/control/gene-corrected composition and intended use of the non-animal model.

c.3139-1G>C Werner Fibroblast WRN-108 Rescue Model PRIMARY_CELL_CULTURE

Dermal fibroblasts from a person homozygous for WRN c.3139-1G>C, compared with healthy fibroblasts and a non-targeting ASO, test genotype-matched WRN-108 uptake, splice correction, protein localization, proliferation, senescence, G-quadruplex, and γH2AX readouts. This cellular model cannot establish chronic ulcer healing or systemic efficacy.

Organism

human NCBITaxon:9606

Cell source

Patient-derived dermal fibroblasts (Coriell AG12795) and healthy control fibroblasts

Culture

Primary fibroblast monolayer with transfection-free WRN-108 exposure

Publication

PMID:42095135

Pathograph links

WRN-108-Directed Exon 27 Skipping Measures the exon 25-exon 28 splice junction after WRN-108 exposure.

Show evidence (1 reference)

PMID:42095135 SUPPORT In Vitro

"subsequent DNA sequencing confirmed exon 25–28 junction formation"

Direct junction sequencing validates the modeled splice-effector state.

Restored Partial WRN Expression and Nuclear Localization Measures WRN protein abundance/localization and downstream genome-maintenance readouts.

Show evidence (1 reference)

PMID:42095135 SUPPORT In Vitro

"Treatment improved cell proliferation and reduced senescence-associated markers, G-quadruplex accumulation, and γH2AX signaling, consistent with partial restoration of WRN-dependent genome maintenance functions."

Functional cellular rescue supports partial WRN restoration while not substituting for a wound-healing endpoint.

Show evidence (1 reference)

PMID:42095135 SUPPORT In Vitro

"In WS patient-derived fibroblasts, WRN-108 efficiently induced exon 27 skipping, restored WRN protein expression, and re-established its nuclear localization."

Directly defines the model, intervention, and primary molecular outputs.

🐁

Animal Models

2

Telomere-limited Wrn-null mouse (mTerc-/- Wrn-/-)

Wrn-null mice on a telomerase-proficient background are essentially unaffected, which for years made WS look untranslatable to the mouse. Crossing Wrn deficiency onto a Terc-null background and breeding to late generations exhausts the mouse's long telomere reserve and unmasks a Werner-like syndrome. The model demonstrates that telomere reserve is rate-limiting in this engineered mouse background; it does not by itself establish telomere attrition as the primary human organismal trigger.

Species

Mouse

Genotype

Wrn-/- Terc-/- (late generation)

Publication

PMID:15235603

Pathograph links

Telomere Maintenance Failure recapitulates fidelity: high Late-generation double-null mice demonstrate that telomere exhaustion can precipitate a Werner-like phenotype from Wrn loss in this engineered model.

Limitations: The requirement for an engineered telomerase-null background is itself a species difference: laboratory mice have telomeres far longer than humans, so the model reconstructs a human baseline rather than reproducing one. Conclusions about the ordering of events transfer better than conclusions about rates.

Show evidence (1 reference)

PMID:15235603 SUPPORT Model Organism

"the lack of a disease phenotype in Wrn-deficient mice with long telomeres implicate telomere attrition in the pathogenesis of Werner syndrome"

States the negative result in long-telomere Wrn-null mice that motivates the telomere-limited cross.

Segmental Progeroid Tissue Failure recapitulates fidelity: moderate The double-null mice develop premature death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts.

Limitations: Recapitulation is of the progeroid features as a set; the model has not been shown to reproduce the specifically WS-discordant distribution (distal-predominant osteoporosis, posterior subcapsular rather than nuclear cataract) that distinguishes WS from ordinary aging in humans.

Readouts

Werner-like premature aging phenotype

Direction: INCREASED

Interpretation: Appearance of the progeroid feature set in late-generation double-null mice but not in Wrn-null mice with long telomeres.

Show evidence (1 reference)

PMID:15235603 SUPPORT Model Organism

"telomere dysfunction elicits a classical Werner-like premature aging syndrome typified by premature death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts"

Reports the specific progeroid features scored in the model.

Show evidence (1 reference)

PMID:15235603 SUPPORT Model Organism

"In late-generation mice null with respect to both Wrn and Terc (encoding the telomerase RNA component)"

Defines the genotype and generation requirement for the model to be informative.

Wrn-null mouse on a telomerase-proficient background

The simple Wrn knockout, which does not develop an overt progeroid phenotype. Recorded here as an explicit negative result rather than omitted, because the absence of a phenotype is itself the informative finding.

Species

Mouse

Genotype

Wrn-/-

Publication

PMID:15235603

Pathograph links

Segmental Progeroid Tissue Failure fails to recapitulate fidelity: low Wrn deficiency alone does not produce a Werner-like syndrome in mice with long telomeres.

Limitations: The failure is attributable to the mouse's long telomere reserve rather than to WRN having a different function in mice, so this model should not be cited as evidence against a WRN-centred mechanism in humans — only against a telomere-independent one.

Show evidence (1 reference)

PMID:15235603 SUPPORT Model Organism

"the lack of a disease phenotype in Wrn-deficient mice with long telomeres"

Directly reports the absence of a disease phenotype in the single-null model.

{ }

Source YAML

click to show

name: Werner Syndrome
creation_date: "2026-08-20T00:00:00Z"
category: Mendelian
description: >-
  Werner syndrome (WS, "progeria of the adult") is a rare autosomal recessive
  segmental progeroid syndrome caused by biallelic null mutations in WRN, which
  encodes a RecQ-family DNA helicase that uniquely also carries a 3'->5'
  exonuclease domain in its N-terminal region. Development is normal until
  adolescence; the first sign is absence of the pubertal growth spurt, and from
  the third decade patients acquire an aged appearance with skin atrophy, loss of
  subcutaneous fat, scleroderma-like skin changes, premature graying and thinning
  of hair, and near-universal bilateral posterior subcapsular cataracts. A
  cluster of common age-related disorders follows in middle age: type 2 diabetes
  mellitus, hypogonadism, osteoporosis, premature atherosclerosis, and
  malignancy. WRN participates in DNA repair, recombination, replication and
  telomere maintenance; its loss produces genomic instability and a severely
  restricted replicative capacity in cultured cells. Telomere attrition is one
  experimentally supported, potentially rate-limiting route from WRN loss to
  senescence, but its primacy in human disease remains unresolved. The cancer
  spectrum is distinctive and does not mirror ordinary
  aging: thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcomas,
  primary bone neoplasms and leukemia/myelodysplasia predominate, and the
  mesenchymal weighting is markedly higher than in age-matched controls. Cancer
  and myocardial infarction are the usual causes of death; an international
  cohort historically reported a median age at death of 54 years. There is no
  cure; management is directed at complications and surveillance. A small
  randomized crossover trial provides early evidence for nicotinamide riboside,
  while a genotype-restricted exon-skipping ASO remains preclinical. Notably,
  the same WRN helicase activity that is lost in WS is a
  synthetic lethal dependency in microsatellite-unstable cancers, making WRN a
  drug target in sporadic oncology.
parents:
- Genetic Disease
disease_term:
  preferred_term: Werner syndrome
  term:
    id: MONDO:0010196
    label: Werner syndrome
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010196
      label: Werner syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for this Werner syndrome entry.
external_assertions:
- name: OMIM Werner syndrome
  source: OMIM
  assertion_type: disease_record
  external_id: OMIM:277700
  description: >-
    OMIM phenotype entry for Werner syndrome, the WRN-related adult-onset
    progeroid syndrome.
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:26993153
      reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "It is caused by null mutations of the WRN gene, which encodes a member of the RECQ family of DNA helicases."
      explanation: >-
        WS is a single-gene disorder caused by null mutations in WRN, supporting
        classification under genetics.
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:23573208
      reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "WS confers a strong predisposition to several specific types of neoplasia."
      explanation: >-
        WS is a cancer predisposition syndrome with markedly elevated
        type-specific neoplasia risk, supporting oncology classification.
  nih_research_priority:
  - classification_value: NIH_HT_89_cellular_quiescence_senescence_cell_death_in
    notes: >-
      The WS pathograph runs through replicative senescence and genomic
      instability and conforms to the genomic_instability_aging,
      telomere_attrition and cellular_senescence modules, making this entry a
      relevant model for NIH Highlighted Topic 89 (cellular quiescence,
      senescence, and cell death in aging and disease).
inheritance:
- name: Autosomal recessive
  description: >-
    Classical WS is caused by homozygous or compound heterozygous loss-of-function
    variants in WRN. Virtually all WRN variants found in clinically ascertained
    patients are functional null alleles.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It is caused by null mutations of the WRN gene, which encodes a member of the RECQ family of DNA helicases."
    explanation: >-
      Establishes WS as caused by null WRN alleles; the recessive mechanism
      requires both copies to be inactivated.
  - reference: PMID:903377
    reference_title: "A retarded rate of DNA replication and normal level of DNA repair in Werner's syndrome fibroblasts in culture."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "patients with Werner's syndrome (WS) of an autosomal recessive premature aging disease"
    explanation: Independent statement that WS is autosomal recessive.
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Werner syndrome is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a WRN pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: >-
      States the inheritance mode together with the quantitative sib recurrence
      risks, which is what the mode means operationally for a family.
prevalence:
- population: Japan
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  percentage: 0.6024096386
  rate_per_100000: 602.4096386
  notes: >-
    Estimated Japanese heterozygote frequency is about 1 in 166 (0.6024%, or
    602.4 carriers per 100,000). This is a carrier-frequency estimate, not the
    prevalence of affected individuals.
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In the Japanese population, the heterozygote frequency is estimated to be 1/166"
    explanation: >-
      Directly supplies the 1-in-166 carrier estimate used for the structured
      percentage, rate per 100,000, and ABOVE_1_IN_1000 band.
pathophysiology:
- name: WRN Helicase-Exonuclease Loss of Function
  biological_scale: MOLECULAR
  description: >
    Biallelic null variants in WRN abolish a 1,432-amino-acid nuclear protein
    that combines an ATP-dependent 3'->5' DNA helicase with an N-terminal 3'->5'
    exonuclease domain. The combination of the two catalytic activities in one
    polypeptide is unique among the five human RecQ helicases. Most disease
    alleles are stop codons, small indels or splice variants that truncate the
    protein and remove its C-terminal nuclear localization signal, so the residual
    product is excluded from the nucleus or degraded; the effect is loss of WRN
    function rather than a variant protein with altered activity.
  genes:
  - preferred_term: WRN
    term:
      id: hgnc:12791
      label: WRN
  molecular_functions:
  - preferred_term: WRN 3'->5' DNA helicase activity
    term:
      id: GO:0003678
      label: DNA helicase activity
    modifier: LOSS_OF_FUNCTION
  - preferred_term: WRN 3'->5' exonuclease activity
    term:
      id: GO:0008408
      label: 3'-5' exonuclease activity
    modifier: LOSS_OF_FUNCTION
  downstream:
  - target: Impaired WRN-Dependent Replication Progression
    description: >
      Loss of nuclear WRN slows DNA-chain elongation and compromises handling of
      structured replication intermediates.
  - target: Telomere Maintenance Failure
    description: >
      WRN is the RecQ helicase that resolves G-quadruplex and four-way-junction
      structures at telomeric repeats, so its loss acts directly on telomere
      replication.
  - target: NAD+ Depletion
    description: >
      Patient samples and experimental models link WRN loss to reduced NMNAT1
      expression and depletion of the NAD+ pool.
  - target: SHOX Promoter G-Quadruplex Persistence
    description: >
      Loss of WRN helicase activity prevents efficient unwinding of a
      G-quadruplex in the SHOX promoter in stem-cell and zebrafish models.
  - target: Retrotransposon-Derived dsRNA Accumulation in WS Macrophages
    description: >
      In a patient-derived iPSC model, WRN deficiency is associated with
      retrotransposon derepression and cytoplasmic double-stranded RNA.
  evidence:
  - reference: PMID:8602509
    reference_title: "Positional cloning of the Werner's syndrome gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The predicted protein is 1432 amino acids in length and shows significant similarity to DNA helicases."
    explanation: >-
      The original positional cloning study identifies the WS gene product as a
      putative DNA helicase of 1,432 residues.
  - reference: PMID:8602509
    reference_title: "Positional cloning of the Werner's syndrome gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One of the these mutations, which results in a frameshift and a predicted truncated protein"
    explanation: >-
      Documents truncating WRN alleles as the disease mechanism, consistent with
      loss of function.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A unique feature of the WRN helicase is the presence of an exonuclease domain in its N-terminal region."
    explanation: >-
      Establishes the dual helicase-exonuclease architecture that distinguishes
      WRN from the other human RecQ helicases.
- name: c.3139-1G>C-Dependent WRN Pre-mRNA Missplicing
  role: therapeutic_vulnerability
  biological_scale: MOLECULAR
  conforms_to: "antisense_oligonucleotide_therapy#Pathogenic Pre-mRNA Missplicing"
  description: >-
    In the genotype-specific subgroup homozygous for WRN c.3139-1G>C, disruption
    of the intron-25 splice acceptor causes exon 26 skipping, a frameshift, and a
    premature stop in exon 27. This therapeutic vulnerability is not asserted
    for other WRN genotypes or for Werner syndrome generally.
  genes:
  - preferred_term: WRN
    term:
      id: hgnc:12791
      label: WRN
  biological_processes:
  - preferred_term: RNA splicing
    term:
      id: GO:0008380
      label: RNA splicing
    modifier: ABNORMAL
  downstream:
  - target: WRN Helicase-Exonuclease Loss of Function
    description: >-
      Exon 26 skipping shifts the reading frame and introduces a premature stop,
      preventing production of functional nuclear WRN.
    causal_link_type: DIRECT
  - target: WRN-108-Directed Exon 27 Skipping
    description: >-
      Only when sequence-matched WRN-108 is administered, steric occupancy of
      exon 27 redirects splicing to an exon 25-exon 28 product.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42095135
      reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In WS patient-derived fibroblasts, WRN-108 efficiently induced exon 27 skipping, restored WRN protein expression, and re-established its nuclear localization."
      explanation: >-
        Patient fibroblasts directly demonstrate the intervention-conditioned
        transition from pathogenic missplicing to exon 27 skipping.
  evidence:
  - reference: PMID:42095135
    reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "c.3139-1G>C, which leads to exon 26 skipping"
    explanation: >-
      The patient genotype and its abnormal exon-26-skipping event define the
      restricted untreated RNA vulnerability.
- name: WRN-108-Directed Exon 27 Skipping
  role: effector
  biological_scale: MOLECULAR
  conforms_to: "antisense_oligonucleotide_therapy#ASO-Directed Splice Redirection"
  description: >-
    In c.3139-1G>C-homozygous patient fibroblasts exposed to WRN-108, induced
    skipping of exon 27 joins exon 25 to exon 28 and restores the open reading
    frame. This is an investigational, treatment-conditioned state.
  genes:
  - preferred_term: WRN
    term:
      id: hgnc:12791
      label: WRN
  biological_processes:
  - preferred_term: RNA splicing
    term:
      id: GO:0008380
      label: RNA splicing
  downstream:
  - target: Restored Partial WRN Expression and Nuclear Localization
    description: >-
      The in-frame exon 25-exon 28 transcript supports expression of a shortened
      WRN protein retaining the nuclear localization signal.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:42095135
      reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "WRN-108 efficiently induces exon 27 skipping and restores the reading frame disrupted by the pathogenic mutation, resulting in robust re-expression of WRN protein with nuclear localization under transfection-free conditions."
      explanation: >-
        Paired RNA, protein, and localization measurements connect splice
        redirection to the productive molecular output.
  evidence:
  - reference: PMID:42095135
    reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "subsequent DNA sequencing confirmed exon 25–28 junction formation"
    explanation: >-
      Sequencing directly verifies the WRN-108-induced splice junction.
- name: Restored Partial WRN Expression and Nuclear Localization
  role: consequence
  biological_scale: MOLECULAR
  conforms_to: "antisense_oligonucleotide_therapy#Restored Productive Transcript and Protein Expression"
  description: >-
    WRN-108-treated c.3139-1G>C patient fibroblasts re-express a shortened WRN
    protein that localizes to nuclei and partially restores genome-maintenance
    readouts. This preclinical molecular rescue does not establish wound healing
    or clinical benefit.
  genes:
  - preferred_term: WRN
    term:
      id: hgnc:12791
      label: WRN
  evidence:
  - reference: PMID:42095135
    reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Treatment improved cell proliferation and reduced senescence-associated markers, G-quadruplex accumulation, and γH2AX signaling, consistent with partial restoration of WRN-dependent genome maintenance functions."
    explanation: >-
      Patient-fibroblast functional readouts support partial rather than complete
      restoration of WRN-dependent cellular functions.
- name: Impaired WRN-Dependent Replication Progression
  biological_scale: CELLULAR
  conforms_to: "genomic_instability_aging#Declining Genome Maintenance and Erroneous Repair"
  description: >
    WS fibroblasts show specifically slowed DNA-chain elongation while repair of
    X-ray-induced single-strand breaks and UV damage remains normal. This node
    therefore represents impaired replication progression and structured-DNA
    handling, not a global DNA-repair deficiency. More detailed fork intermediates
    have been proposed in newer cell studies, but are not asserted here without a
    directly cached primary source.
  biological_processes:
  - preferred_term: DNA replication
    term:
      id: GO:0006260
      label: DNA replication
    modifier: DECREASED
  cell_types:
  - preferred_term: skin fibroblast
    term:
      id: CL:0002620
      label: skin fibroblast
  downstream:
  - target: Genomic Instability
    description: >
      Persistently impaired replication progression contributes to accumulated
      chromosomal damage and rearrangement.
  - target: Accelerated Replicative Senescence
    description: >
      Slowed replication and restricted replicative potential exhaust the
      proliferative capacity of WS cells.
  evidence:
  - reference: PMID:903377
    reference_title: "A retarded rate of DNA replication and normal level of DNA repair in Werner's syndrome fibroblasts in culture."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "only the elongation rate of DNA chains, estimated by the molecular weight increase, was significantly slower during early passages in WS cells than in normal Hayflick Phase II fibroblasts"
    explanation: >-
      Direct measurement showing that DNA chain elongation, not repair capacity,
      is the defective step in WS fibroblasts.
  - reference: PMID:903377
    reference_title: "A retarded rate of DNA replication and normal level of DNA repair in Werner's syndrome fibroblasts in culture."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Five WS strains exhibited normal levels of sensitivity toward X-ray and UV killings and repair of X-ray induced single strand breaks of DNA (rejoining) and UV damage to DNA (unscheduled DNA synthesis)."
    explanation: >-
      Negative result delimiting the defect: excision and single-strand break
      repair are intact, so this node should not be read as a global repair
      failure.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Biochemical and cell biological studies during the past decade have demonstrated involvements of the WRN protein in multiple DNA transactions, including DNA repair, recombination, replication and transcription."
    explanation: >-
      Summarizes the DNA transactions supported by WRN, while the direct
      fibroblast experiment narrows this node to the demonstrated replication
      defect.
- name: Telomere Maintenance Failure
  biological_scale: MOLECULAR
  conforms_to: "telomere_attrition#Progressive Telomere Attrition"
  description: >
    Telomeric TTAGGG repeats form G-quadruplex structures that are preferred WRN
    substrates, and telomere replication requires resolution of four-way junctions
    at D- and T-loops. In the absence of WRN these structures can persist and
    telomere replication is impaired. Telomerase rescue in patient fibroblasts
    and the phenotype of late-generation Wrn-/- Terc-/- mice support telomere
    reserve as a rate-limiting model. They do not establish telomere attrition as
    the unique proximate trigger of the human multisystem phenotype.
  biological_processes:
  - preferred_term: telomere maintenance
    term:
      id: GO:0000723
      label: telomere maintenance
    modifier: DECREASED
  downstream:
  - target: Accelerated Replicative Senescence
    description: >
      Critically short, unprotected telomeres trigger a persistent DNA damage
      response and senescence.
  - target: Genomic Instability
    description: >
      Uncapped telomeres promote chromosomal end fusions and telomere sister
      chromatid exchange.
  evidence:
  - reference: PMID:15235603
    reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we show that the varied and complex cellular phenotypes of Werner syndrome are precipitated by exhaustion of telomere reserves in mice"
    explanation: >-
      Mouse genetics show that telomere exhaustion can precipitate a Werner-like
      phenotype in a sensitized double-null model; species and engineered-background
      limitations prevent direct assignment of human causal primacy.
  - reference: PMID:15235603
    reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The capacity of enforced telomerase expression to rescue premature senescence of cultured cells from individuals with Werner syndrome"
    explanation: >-
      Telomerase rescue places telomere reserve upstream of premature senescence
      in cultured WS fibroblasts, not necessarily upstream of every human feature.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A role of the WRN protein in telomere maintenance could explain many of the WS phenotypes."
    explanation: >-
      The review explicitly frames telomere maintenance as an explanatory
      hypothesis ("could explain"), supporting calibrated rather than definitive
      language.
- name: Genomic Instability
  biological_scale: CELLULAR
  conforms_to: "genomic_instability_aging#Accumulation of Somatic Mutations and Genomic Damage"
  description: >
    WS cells display "variegated translocation mosaicism" — multiple, variable,
    predominantly stable chromosomal rearrangements differing between clones —
    together with elevated telomere sister chromatid exchange and increased common
    fragile site expression. This is the mutator phenotype that underlies the WS
    cancer predisposition, and it is the shared feature that groups WS with the
    other RecQ disorders (Bloom syndrome, Rothmund-Thomson syndrome) as
    chromosomal instability syndromes.
  biological_processes:
  - preferred_term: DNA repair
    term:
      id: GO:0006281
      label: DNA repair
    modifier: ABNORMAL
  downstream:
  - target: Cancer Predisposition with Mesenchymal Weighting
    description: >
      Accumulated chromosomal aberrations drive clonal evolution toward the
      characteristic WS neoplasm spectrum.
  evidence:
  - reference: PMID:23573208
    reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Werner syndrome (WS) is an autosomal recessive genetic instability"
    explanation: >-
      Systematic review characterizes WS as a genetic instability syndrome, the
      framing this node encodes.
  - reference: PMID:15235603
    reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "as well as increased chromosomal instability and cancer, particularly nonepithelial malignancies typical of Werner syndrome"
    explanation: >-
      The telomere-depleted mouse model reproduces both the chromosomal
      instability and the nonepithelial (mesenchymal) tumor bias of human WS.
- name: Accelerated Replicative Senescence
  biological_scale: CELLULAR
  conforms_to: "cellular_senescence#Senescence-Associated Cell Cycle Arrest"
  description: >
    WS fibroblasts have a markedly restricted replicative lifespan and reduced
    plating efficiency relative to normal fibroblasts cultured in parallel, and
    accumulate DNA damage foci. Premature exhaustion of the proliferative reserve
    of mesenchymal and other renewable cell populations is the cellular event most
    directly connected to the progeroid tissue phenotypes. Enforced telomerase
    expression rescues premature senescence in cultured WS fibroblasts, while
    adipose and iPSC-derived models also implicate non-telomeric inflammatory
    programs; the relative contribution in patients is unresolved.
  biological_processes:
  - preferred_term: replicative senescence
    term:
      id: GO:0090399
      label: replicative senescence
    modifier: INCREASED
  cell_types:
  - preferred_term: skin fibroblast
    term:
      id: CL:0002620
      label: skin fibroblast
  downstream:
  - target: Segmental Progeroid Tissue Failure
    description: >
      Loss of proliferative reserve in renewable tissues manifests as the
      accelerated-aging phenotypes of WS.
  - target: Senescence-Associated Adipogenic Failure
    description: >-
      In a primary adipose stromal-cell comparison, early senescence and a SASP
      accompany impaired adipogenesis and insulin signaling.
  evidence:
  - reference: PMID:903377
    reference_title: "A retarded rate of DNA replication and normal level of DNA repair in Werner's syndrome fibroblasts in culture."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "plating efficiencies as well as the replicative potentials of five WS strains were more limited than those of normal cells under the identical culture conditions"
    explanation: >-
      Directly measures the restricted replicative potential of WS fibroblasts
      against normal controls in the same culture conditions.
  - reference: PMID:15235603
    reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This mouse model also showed accelerated replicative senescence and accumulation of DNA-damage foci in cultured cells"
    explanation: >-
      Confirms accelerated replicative senescence and DNA damage focus
      accumulation in the telomere-limited Wrn-null model.
- name: NAD+ Depletion
  biological_scale: MOLECULAR
  description: >-
    WS patient samples and invertebrate models show depletion of NAD+. WRN was
    reported to regulate transcription of NMNAT1, linking the nuclear WRN lesion
    to reduced NAD+ biosynthetic capacity. The degree and tissue distribution of
    this deficit in patients remain incompletely mapped.
  downstream:
  - target: Impaired Mitophagy and Mitochondrial Quality Control
    description: >-
      Reduced NAD+ availability is associated with impaired mitophagy; NAD+
      repletion improves mitochondrial quality through DCT-1- and ULK-1-dependent
      mitophagy in experimental models.
  evidence:
  - reference: PMID:31754102
    reference_title: NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we report impaired mitophagy and depletion of NAD+, a fundamental ubiquitous molecule, in WS patient samples and WS invertebrate models."
    explanation: >-
      The human-sample clause supports NAD+ depletion in patient material; it is
      kept separate from the invertebrate-model arm of the same sentence.
  - reference: PMID:31754102
    reference_title: NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here we report impaired mitophagy and depletion of NAD+, a fundamental ubiquitous molecule, in WS patient samples and WS invertebrate models."
    explanation: >-
      The invertebrate-model clause supports the experimental organism arm and is
      not relabeled as human or in-vitro evidence.
- name: Impaired Mitophagy and Mitochondrial Quality Control
  biological_scale: CELLULAR
  conforms_to: "mitochondrial_dysfunction#Impaired Mitophagy and Quality Control"
  description: >-
    Experimental WS systems show impaired clearance of dysfunctional
    mitochondria. NAD+ repletion improves mitochondrial quality through the
    mitophagy regulators DCT-1 and ULK-1 and extends lifespan in invertebrate WS
    models, but those organismal rescues are not human treatment evidence.
  biological_processes:
  - preferred_term: mitophagy
    term:
      id: GO:0000422
      label: autophagy of mitochondrion
    modifier: DECREASED
  evidence:
  - reference: PMID:31754102
    reference_title: NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "NAD+ repletion restores NAD+ metabolic profiles and improves mitochondrial quality through DCT-1 and ULK-1-dependent mitophagy."
    explanation: >-
      Genetic dependence on mitophagy regulators supports the quality-control
      mechanism in experimental WS systems.
- name: SHOX Promoter G-Quadruplex Persistence
  biological_scale: MOLECULAR
  description: >-
    WRN helicase binds and unwinds a G-quadruplex in the SHOX promoter. WRN loss
    therefore leaves this regulatory structure unresolved in stem-cell and
    zebrafish systems, reducing SHOX transcription. This developmental model
    addresses the short-stature arm and is not a general explanation for adult
    progeroid manifestations.
  downstream:
  - target: Reduced SHOX Transcription and Chondrogenesis
    description: >-
      Persistent promoter G-quadruplex structure reduces SHOX transcription and
      impairs chondrocyte differentiation.
  evidence:
  - reference: PMID:36114168
    reference_title: WRN promotes bone development and growth by unwinding SHOX-G-quadruplexes via its helicase activity in Werner Syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We identify short-stature homeobox (SHOX) as a crucial and direct target of WRN and find that the WRN helicase core regulates the transcriptional expression of SHOX via unwinding G-quadruplexes."
    explanation: >-
      Stem-cell and molecular assays identify the WRN-SHOX promoter interaction
      and the G-quadruplex-unwinding step.
- name: Reduced SHOX Transcription and Chondrogenesis
  biological_scale: CELLULAR
  description: >-
    WRN-null hESC/hMSC differentiation and zebrafish models have reduced SHOX,
    impaired chondrogenesis, and short body length. SHOX overexpression rescues
    the developmental defect in both systems, placing SHOX downstream of WRN for
    this phenotype.
  downstream:
  - target: Short Stature
    description: >-
      Reduced SHOX-dependent chondrogenesis directly models the absent pubertal
      growth spurt and short body length.
  evidence:
  - reference: PMID:36114168
    reference_title: WRN promotes bone development and growth by unwinding SHOX-G-quadruplexes via its helicase activity in Werner Syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "genetic overexpression of SHOX or shox expression rescues the bone developmental deficiency induced in WRN/wrn-null mutants both in vitro and in vivo."
    explanation: >-
      The in-vitro arm supports SHOX rescue during stem-cell differentiation and
      is kept distinct from the zebrafish result.
  - reference: PMID:36114168
    reference_title: WRN promotes bone development and growth by unwinding SHOX-G-quadruplexes via its helicase activity in Werner Syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "genetic overexpression of SHOX or shox expression rescues the bone developmental deficiency induced in WRN/wrn-null mutants both in vitro and in vivo."
    explanation: >-
      The in-vivo zebrafish arm supports organismal rescue and is kept distinct
      from the cell-culture evidence.
- name: Retrotransposon-Derived dsRNA Accumulation in WS Macrophages
  biological_scale: CELLULAR
  description: >-
    In WS iPSC-derived macrophages, reduced H3K9me3 is associated with
    retrotransposable-element derepression and cytoplasmic double-stranded RNA.
    This is a model-specific vascular-inflammatory mechanism and has not been
    demonstrated as a systemic causal intermediate in patients.
  downstream:
  - target: DHX58-Dependent Type I Interferon Inflammation
    description: >-
      Retrotransposon-derived double-stranded RNA engages the DHX58-dependent
      cytoplasmic RNA-sensing pathway.
  evidence:
  - reference: PMID:38858384
    reference_title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "H3K9me3 inversely correlates with RTEs, activating the DHX58-dependent RNA sensing pathway."
    explanation: >-
      Multi-omic and perturbation data in patient-derived macrophages support the
      RTE-to-DHX58 sensing step.
- name: DHX58-Dependent Type I Interferon Inflammation
  biological_scale: CELLULAR
  mechanism_confidence: PROVISIONAL
  description: >-
    RNA sensing in WS iPSC-derived macrophages drives type I interferon signaling,
    senescence, and inflammatory effects on co-cultured endothelial and vascular
    smooth-muscle cells. Interferon silencing reverses cellular readouts, but the
    experiment is a non-animal model rather than a clinical intervention.
  downstream:
  - target: Premature Atherosclerosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      This provisional, model-extrapolated edge places the macrophage inflammatory
      state upstream of endothelial dysfunction and smooth-muscle switching in a
      two-dimensional co-culture; it does not establish lesion formation in
      patients.
    evidence:
    - reference: PMID:38858384
      reference_title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "WS-iMφs induce endothelial dysfunction in WS-iVECs and synthetic phenotype switching in WS-iVSMCs."
      explanation: >-
        Directly supports the vascular-cell effects in co-culture; the inference
        from those readouts to human premature atherosclerosis remains indirect
        and provisional.
  evidence:
  - reference: PMID:38858384
    reference_title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Silencing type I IFN signaling rescues proliferation and suppresses senescence and inflammation, suggesting atherosclerosis treatment in WS."
    explanation: >-
      Pathway silencing supplies intervention evidence for the modeled IFN-driven
      senescence and inflammation, without establishing patient efficacy.
- name: Senescence-Associated Adipogenic Failure
  biological_scale: CELLULAR
  description: >-
    Adipose stromal vascular fraction from one person with WS showed premature
    senescence, increased SASP genes, suppressed adipogenesis, and impaired insulin
    signaling relative to one healthy donor. Four-patient imaging and clamp data
    associated subcutaneous fat loss with insulin resistance. The cellular
    comparison is informative but very small.
  downstream:
  - target: Loss of Subcutaneous Adipose Tissue in Limbs
    description: >-
      The patient-cell and imaging study directly connects failed adipogenesis
      with loss of the subcutaneous fat compartment.
  evidence:
  - reference: PMID:37793000
    reference_title: Senescence-associated inflammation and inhibition of adipogenesis in subcutaneous fat in Werner syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Adipose-derived stem cells from the stromal vascular fraction derived from WS subcutaneous adipose tissues (WSVF) showed early replicative senescence and a significant increase in the expression of senescence-associated secretory phenotype (SASP) markers."
    explanation: >-
      The primary-cell comparison directly connects early senescence and SASP to
      the affected adipose compartment.
  - reference: PMID:37793000
    reference_title: Senescence-associated inflammation and inhibition of adipogenesis in subcutaneous fat in Werner syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical data from four Japanese patients with WS revealed significant associations between the decrease of areas of subcutaneous fat and increased insulin resistance measured by the glucose clamp."
    explanation: >-
      The small human series links the adipose phenotype to insulin resistance;
      it does not estimate population frequency.
- name: Segmental Progeroid Tissue Failure
  biological_scale: ORGANISM
  conforms_to: "genomic_instability_aging#DNA-Damage-Driven Cellular Dysfunction and Aging"
  description: >
    The organismal phenotype is segmental rather than global: some age-related
    changes are strikingly accelerated (cataract, hair graying and loss, skin
    atrophy, osteoporosis, atherosclerosis, type 2 diabetes) while others
    characteristic of normal aging are absent — Alzheimer-type dementia and
    increased amyloid deposition are not features, and the osteoporosis is worse
    in distal limb bones than in the vertebral column, the reverse of ordinary
    aging. The segmental pattern is a substantive constraint on the "accelerated
    aging" framing and should not be smoothed over: WS is not normal aging run
    fast.
  downstream:
  - target: Bilateral Cataracts
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Premature Graying and Thinning of Hair
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Alopecia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Type 2 Diabetes Mellitus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Osteoporosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Werner syndrome (WS) is a prototypical segmental progeroid syndrome characterized by multiple features consistent with accelerated aging."
    explanation: >-
      Establishes the segmental progeroid framing that this node encodes.
  - reference: PMID:15235603
    reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "telomere dysfunction elicits a classical Werner-like premature aging syndrome typified by premature death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts"
    explanation: >-
      Enumerates the specific organismal features recapitulated when telomere
      reserves are exhausted in a Wrn-null background.
- name: Cancer Predisposition with Mesenchymal Weighting
  biological_scale: ORGANISM
  description: >
    WS confers a strong, type-specific predisposition to a narrow set of
    neoplasms rather than a general increase in cancer. Six tumor types —
    thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcoma,
    leukemia and pre-leukemic marrow conditions, and primary bone neoplasms —
    account for about two-thirds of all reported neoplasms in WS patients, and
    the standardized incidence ratios in Japan-resident patients are elevated for
    all of these except leukemia. The mesenchymal and neural-crest weighting is
    the mechanistically informative part: it is the opposite of the
    epithelial-dominated spectrum of ordinary aging. The lineage bias remains
    mechanistically unresolved and should not be attributed to a specific
    telomere-maintenance pathway without direct evidence.
  downstream:
  - target: Neoplasm
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Thyroid Carcinoma
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Malignant Melanoma
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Soft Tissue Sarcoma
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Meningioma
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Osteosarcoma
    description: >-
      Osteosarcoma is retained as a narrower, registry-documented member of the
      broader primary-bone-neoplasm spectrum.
    evidence:
    - reference: PMID:33373317
      reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "comprised lung cancer, lung adenocarcinoma, undifferentiated pleomorphic sarcoma, fibrosarcoma, osteosarcoma, colorectal cancer, follicular thyroid cancer, and melanoma."
      explanation: >-
        The modern registry explicitly names osteosarcoma, avoiding an inference
        from the systematic review's broader primary-bone-neoplasm category.
  evidence:
  - reference: PMID:23573208
    reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent neoplasms in WS patients, representing 2/3 of all reports, were thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcomas, leukemia and pre-leukemic conditions of the bone marrow, and primary bone neoplasms."
    explanation: >-
      Defines the WS neoplasm spectrum from a study population of 189 patients
      with 248 neoplasms.
  - reference: PMID:23573208
    reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cancer risk defined by SIRs was significantly elevated in Japan-resident WS patients for the six most frequent neoplasms except leukemia"
    explanation: >-
      Quantifies the risk elevation and records the leukemia exception, which
      this node preserves rather than generalizing away.
phenotypes:
- name: Prematurely Aged Appearance
  category: Constitutional
  diagnostic: true
  frequency: VERY_FREQUENT
  description: >-
    The adult-onset aged appearance that defines Werner syndrome as the
    prototypical adult progeria. Development is normal through the first decade;
    the aged phenotype then assembles over the second and third decades from
    premature graying and thinning of scalp hair, scleroderma-like skin, bird-like
    facies, loss of limb subcutaneous fat, and short stature. This is the
    phenotype on which membership in the Progeroid_Syndromes grouping turns.
  phenotype_term:
    preferred_term: Prematurely aged appearance
    term:
      id: HP:0007495
      label: Prematurely aged appearance
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Werner syndrome is characterized by the premature appearance of features associated with normal aging and cancer predisposition."
    explanation: >-
      GeneReviews opens its clinical description with the premature appearance of
      aging features, the disease-level claim this phenotype records.
- category: Ophthalmologic
  name: Bilateral Cataracts
  description: >
    Bilateral posterior subcapsular cataracts requiring surgery develop in
    virtually all WS patients by the late 20s or early 30s. The posterior
    subcapsular location distinguishes them from the nuclear cataracts typical of
    normal aging — one of the discordances between WS and ordinary senescence.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Bilateral posterior subcapsular cataract
    term:
      id: HP:0007787
      label: Posterior subcapsular cataract
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places bilateral ocular cataracts in the subsequent group
      occurring in the 30s; YOUNG_ADULT records that broad onset category
      without inferring a narrower age.
  - reference: PMID:7712642
    reference_title: "Werner's syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Rapidly progressing bilateral cataracts typically occur when patients are in their 20s and 30s."
    explanation: >-
      Establishes bilateral cataracts with third-decade onset as a cardinal WS
      feature.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The cataracts seen in WS are almost always posterior sub-capsular, in contrast to those seen in normal aged people, which are typically nuclear cataracts."
    explanation: >-
      Directly supports the posterior subcapsular localization represented by
      HP:0007787 and preserves the source's exact hyphenation.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardinal signs include bilateral cataracts (present in 99% of WS cases), premature graying and/or thinning of scalp hair (100%), characteristic dermatologic changes (96%) and short stature (95%)"
    explanation: >-
      The locally quoted 99% estimate supports the VERY_FREQUENT band without
      asserting absolute penetrance.
  - reference: PMID:16673358
    reference_title: The spectrum of WRN mutations in Werner syndrome patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical data confirm that the most penetrant phenotype is bilateral ocular cataracts."
    explanation: >-
      The molecularly characterized international cohort independently identifies
      bilateral cataracts as the most penetrant phenotype.
- category: Integument
  name: Premature Graying and Thinning of Hair
  description: >
    Graying and thinning of scalp hair, often with frank alopecia, begins around
    puberty and is one of the four cardinal diagnostic signs.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Premature graying of hair
    term:
      id: HP:0002216
      label: Premature graying of hair
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places premature graying and thinning among findings usually
      observed in the 20s; YOUNG_ADULT records that broad onset category
      without inferring a narrower age.
  - reference: PMID:7712642
    reference_title: "Werner's syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The disease generally becomes apparent around puberty, with growth arrest and thinning and graying of hair."
    explanation: >-
      Documents peripubertal onset of hair graying and thinning as a presenting
      feature.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardinal signs include bilateral cataracts (present in 99% of WS cases), premature graying and/or thinning of scalp hair (100%), characteristic dermatologic changes (96%) and short stature (95%)"
    explanation: >-
      Dedicated frequency evidence for the VERY_FREQUENT band on this phenotype:
      all four cardinal signs are reported at 95-100% in the WS registry cohort.
- category: Integument
  name: Alopecia
  description: >
    Progressive loss of scalp hair, up to baldness, accompanies the graying and
    contributes to the aged appearance.
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:7712642
    reference_title: "Werner's syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "thinning and graying of hair or baldness, nail dystrophy or loss, wrinkling and aging of the face"
    explanation: Lists baldness among the dermatologic presentations of WS.
- category: Integument
  name: Scleroderma-like Skin Changes
  description: >
    Tight, atrophic, scleroderma-like skin with loss of subcutaneous fat,
    particularly over the limbs and face, producing the characteristic "pinched"
    facial appearance. This is frequently what brings the patient to a
    dermatologist and is a common source of diagnostic delay, since scleroderma
    itself is the first consideration.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Scleroderma-like skin changes
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places scleroderma-like skin changes among findings usually
      observed in the 20s; YOUNG_ADULT records that broad onset category
      without inferring a narrower age.
  - reference: PMID:7712642
    reference_title: "Werner's syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A dermatologist may be consulted because of the scleroderma-like appearance of the skin"
    explanation: >-
      Confirms scleroderma-like skin change as a presenting dermatologic feature
      of WS.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardinal signs include bilateral cataracts (present in 99% of WS cases), premature graying and/or thinning of scalp hair (100%), characteristic dermatologic changes (96%) and short stature (95%)"
    explanation: >-
      Dedicated frequency evidence for the VERY_FREQUENT band on this phenotype:
      all four cardinal signs are reported at 95-100% in the WS registry cohort.
- category: Integument
  name: Soft-Tissue Calcification
  description: >-
    Ectopic soft-tissue and subcutaneous calcification, especially around chronic
    lower-extremity lesions, is a major WS sign. The HPO term is broader than the
    registry wording but does not falsely restrict the finding to a single tissue.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Ectopic calcification
    term:
      id: HP:0010766
      label: Ectopic calcification
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "that of soft-tissue calcification had increased (76.7% vs. 87.5%,P=0.048)"
    explanation: >-
      The current-registry value of 87.5% supports the VERY_FREQUENT band.
- category: Metabolic
  name: Loss of Subcutaneous Adipose Tissue in Limbs
  description: >-
    Extremity lipoatrophy produces the characteristic thin limbs, often alongside
    preserved or increased visceral fat. Clinical synthesis describes thin limbs
    as frequent, and newer small imaging/clamp data link subcutaneous fat loss to
    insulin resistance.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Loss of subcutaneous adipose tissue in limbs
    term:
      id: HP:0003635
      label: Loss of subcutaneous adipose tissue in limbs
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other features frequently seen in WS include a high pitched hoarse voice (recognizable over the phone), characteristic facial features (a “pinched” facial appearance), thin limbs, truncal obesity, and flat feet."
    explanation: >-
      The clinical synthesis directly lists thin limbs among frequent WS features.
  - reference: PMID:37793000
    reference_title: Senescence-associated inflammation and inhibition of adipogenesis in subcutaneous fat in Werner syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical data from four Japanese patients with WS revealed significant associations between the decrease of areas of subcutaneous fat and increased insulin resistance measured by the glucose clamp."
    explanation: >-
      Small human imaging/clamp data support the metabolic relevance of the
      lipoatrophy, but not its population frequency.
- category: Metabolic
  name: Truncal and Visceral Adiposity
  description: >-
    Truncal or visceral fat accumulation can coexist with low BMI and thin,
    lipoatrophic limbs, producing sarcopenic obesity rather than generalized
    obesity.
  phenotype_term:
    preferred_term: Truncal obesity
    term:
      id: HP:0001956
      label: Truncal obesity
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "thin limbs, truncal obesity, and flat feet."
    explanation: >-
      Directly identifies truncal obesity as part of the characteristic body-fat
      distribution.
  - reference: PMID:37130431
    reference_title: Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with Werner syndrome tended to have sarcopenia obesity (visceral fat increase despite low BMI)."
    explanation: >-
      The current registry supplies the modern visceral-fat/low-BMI context.
- category: Craniofacial
  name: Bird-Like Facies
  description: >-
    A pinched, bird-like facial appearance is a highly characteristic component
    of the WS gestalt. In a modern Japanese registry, approximately 90% of
    participants had the characteristic face together with a high-pitched voice.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Bird-like facies
    term:
      id: HP:0000320
      label: Bird-like facies
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 90% of patients had a characteristic bird-like face and high-pitched voice."
    explanation: >-
      The n=40 registry directly places the facial gestalt in the VERY_FREQUENT
      band.
- category: Otolaryngologic
  name: Abnormally High-Pitched Voice
  description: >
    A high-pitched voice is a characteristic WS feature and is ontologically
    distinct from hoarseness, although older clinical descriptions sometimes use
    both terms. The modern registry reports the high-pitched voice with the
    characteristic face in approximately 90% of participants.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Abnormally high-pitched voice
    term:
      id: HP:0001620
      label: Abnormally high-pitched voice
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places the characteristic vocal change, described there as
      hoarseness, among findings usually observed in the 20s. YOUNG_ADULT
      records that broad timing without conflating hoarseness with the mapped
      high-pitched-voice phenotype or inferring a narrower age.
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 90% of patients had a characteristic bird-like face and high-pitched voice."
    explanation: >-
      Directly supports the high-pitched-voice phenotype and its frequency band.
- category: Integument
  name: Intractable Lower Extremity Ulcers
  description: >
    Indolent, deep, treatment-resistant ulcerations around the Achilles tendons
    and less frequently at the elbows are considered nearly pathognomonic of WS.
    They are associated with extensive subcutaneous calcification and often
    culminate in amputation of the foot or lower limb.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Intractable lower extremity ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places skin ulcers in the subsequent group occurring in the
      30s; YOUNG_ADULT records that broad onset category without inferring a
      narrower age.
  - reference: PMID:7712642
    reference_title: "Werner's syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A dermatologist may be consulted because of the scleroderma-like appearance of the skin, lower-extremity ulcers or calluses"
    explanation: >-
      Records lower-extremity ulceration as one of the dermatologic
      presentations that brings WS patients to clinical attention.
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the percentage of patients with intractable skin ulcers had decreased (87.5% vs. 67.5%,P<0.01)"
    explanation: >-
      The current-registry value of 67.5% supports the FREQUENT band.
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, 15% of patients had a history of foot amputation."
    explanation: >-
      Captures amputation as an occasional severe outcome of the ulcer/vascular
      phenotype rather than an independent disease feature.
- category: Musculoskeletal
  name: Decreased Muscle Mass and Sarcopenic Physique
  description: >-
    Low skeletal-muscle mass, weak grip, and slow gait produce a sarcopenic or
    sarcopenic-obesity phenotype. In the 2020 registry, most patients older than
    40 years met sarcopenia-related thresholds, so the frequency band is
    age-contextual rather than a lifetime all-ages estimate.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Decreased muscle mass
    term:
      id: HP:0003199
      label: Decreased muscle mass
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therefore, in this registry, most patients aged over 40 years had sarcopenia."
    explanation: >-
      Supports a frequent sarcopenic phenotype specifically among patients older
      than 40 years, not an all-ages penetrance estimate.
  - reference: PMID:37130431
    reference_title: Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The grip strength and SMI met the diagnostic criteria for sarcopenia."
    explanation: >-
      The 51-person registry independently supports low muscle mass and strength.
- category: Growth
  name: Short Stature
  description: >
    Absence of the adolescent growth spurt produces short adult stature. It is
    typically the earliest sign of WS and is usually recognized only in
    retrospect, which is a major contributor to the diagnostic delay.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
    onset:
      onset_category: JUVENILE
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The first sign is the lack of a growth spurt during the early teen years."
    explanation: >-
      Directly supports adolescent growth-spurt failure as the origin and first
      sign of short stature. JUVENILE records the early-teen category without
      inferring minimum or maximum ages.
  - reference: PMID:7712642
    reference_title: "Werner's syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The disease generally becomes apparent around puberty, with growth arrest"
    explanation: >-
      Peripubertal growth arrest is the origin of the short stature in WS.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardinal signs include bilateral cataracts (present in 99% of WS cases), premature graying and/or thinning of scalp hair (100%), characteristic dermatologic changes (96%) and short stature (95%)"
    explanation: >-
      Dedicated frequency evidence for the VERY_FREQUENT band on this phenotype:
      all four cardinal signs are reported at 95-100% in the WS registry cohort.
- category: Endocrine
  name: Type 2 Diabetes Mellitus
  description: >
    Insulin-resistant type 2 diabetes appears in middle age as one of the
    age-related disorders accelerated in WS.
  phenotype_term:
    preferred_term: Type II diabetes mellitus
    term:
      id: HP:0005978
      label: Type II diabetes mellitus
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places type 2 diabetes mellitus in the subsequent group
      occurring in the 30s; YOUNG_ADULT records that broad onset category
      without inferring a narrower age.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."
    explanation: >-
      Directly identifies type 2 diabetes as a WS manifestation without treating
      the registry's combined diabetes/impaired-glucose-tolerance percentage as a
      type-2-diabetes-specific frequency.
- category: Metabolic
  name: Dyslipidemia
  description: >-
    Abnormal circulating lipid concentrations are common in WS and contribute to
    cardiovascular risk. The broad HPO term avoids assuming a single lipid
    fraction or direction of abnormality.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormal circulating lipid concentration
    term:
      id: HP:0003119
      label: Abnormal circulating lipid concentration
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Over half of the patients had diabetes, impaired glucose tolerance (67.5%), dyslipidemia (65.0%), and fatty liver (52.5%)."
    explanation: The modern registry directly supports the FREQUENT band.
- category: Hepatic
  name: Hepatic Steatosis
  description: >-
    Fatty liver is a common metabolic manifestation and should be considered in
    longitudinal metabolic and medication monitoring.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Over half of the patients had diabetes, impaired glucose tolerance (67.5%), dyslipidemia (65.0%), and fatty liver (52.5%)."
    explanation: The modern registry directly supports the FREQUENT band.
- category: Cardiovascular
  name: Hypertension
  description: >-
    Adult hypertension is documented and treated in the modern registry. It is
    retained as a comorbidity but is not presented as a cardinal or specifically
    early-onset WS feature; no frequency band is assigned from an unquoted table
    cell.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Calcium antagonists and angiotensin-II receptor blockers were often used for patients with hypertension."
    explanation: >-
      Supports the existence and management of hypertension in the registry but
      does not establish a population-frequency band.
- category: Endocrine
  name: Hypogonadism
  description: >
    Gonadal atrophy and early loss of fertility can develop in the third decade.
  phenotype_term:
    preferred_term: Hypogonadism
    term:
      id: HP:0000135
      label: Hypogonadism
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places hypogonadism in the subsequent group occurring in the
      30s; YOUNG_ADULT records that broad onset category without inferring a
      narrower age.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."
    explanation: >-
      Lists hypogonadism among the middle-age age-related disorders of WS.
- category: Musculoskeletal
  name: Osteoporosis
  description: >
    Osteoporosis develops in middle age with an unusual distribution: it is more
    severe in the distal limb bones than in the vertebral column, the opposite of
    the pattern seen in normal aging. Osteosclerosis of the distal phalanges is
    also highly characteristic.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
    onset:
      onset_category: YOUNG_ADULT
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Early findings (usually observed in the 20s) include premature graying and/or thinning of scalp hair, hoarseness, and scleroderma-like skin changes, followed by bilateral ocular cataracts, type 2 diabetes mellitus, hypogonadism, skin ulcers, and osteoporosis in the 30s."
    explanation: >-
      GeneReviews places osteoporosis in the subsequent group occurring in the
      30s; YOUNG_ADULT records that broad onset category without inferring a
      narrower age.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."
    explanation: Lists osteoporosis among the accelerated age-related disorders of WS.
- category: Cardiovascular
  name: Premature Atherosclerosis
  description: >
    Premature and severe atherosclerosis, arteriolosclerosis and medial
    calcinosis. Modern registry data document hypertension and dyslipidemia as
    common comorbidities, so vascular disease should not be framed as occurring
    without conventional risk factors. Arteriosclerosis obliterans/peripheral
    arterial disease was reported in 15% of the n=40 registry.
  phenotype_term:
    preferred_term: Atherosclerosis
    term:
      id: HP:0002621
      label: Atherosclerosis
  sequelae:
  - target: Myocardial Infarction
    description: >-
      Premature atherosclerotic cardiovascular disease culminates in myocardial
      infarction, one of the two leading reported causes of death in WS.
    evidence:
    - reference: PMID:26993153
      reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The most common causes of death are cancer and myocardial infarction, at a median age of 54"
      explanation: >-
        The review identifies myocardial infarction as a leading fatal vascular
        outcome in WS.
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These disorders include type 2 diabetes mellitus, hypogonadism, osteoporosis, atherosclerosis and malignancies."
    explanation: Lists atherosclerosis among the accelerated age-related disorders of WS.
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A small percentage of patients had a history of atherosclerosis, such as cerebral infarction (0%), angina pectoris or myocardial infarction (2.5%), or arteriosclerosis obliterans (ASO) (15.0%) (Table 2)."
    explanation: >-
      Directly quantifies the peripheral-arterial component as an occasional
      manifestation without assigning that value to all forms of atherosclerosis.
- category: Cardiovascular
  name: Myocardial Infarction
  description: >
    Myocardial infarction is, with cancer, one of the two most common causes of
    death in WS, at a median age of 54.
  phenotype_term:
    preferred_term: Myocardial infarction
    term:
      id: HP:0001658
      label: Myocardial infarction
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common causes of death are cancer and myocardial infarction, at a median age of 54"
    explanation: >-
      Establishes myocardial infarction as a leading cause of death and gives the
      median age at death.
- category: Neoplasia
  name: Neoplasm
  description: >-
    Malignancy is a common late complication, with modern Japanese registries
    reporting about 20-30% of participants affected. This generic phenotype
    captures aggregate burden while the following entries preserve the
    distinctive tumor spectrum.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant tumor was observed in 20.0% of patients"
    explanation: The n=40 registry places aggregate neoplasm burden in the OCCASIONAL band.
  - reference: PMID:37130431
    reference_title: Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant neoplasms were observed from the fifth decade of life (mean onset: 49.7 years) and were observed in approximately 30% of patients during the 3-year survey period."
    explanation: >-
      The 51-person longitudinal registry supplies timing and an updated burden
      estimate near the upper boundary of the OCCASIONAL band.
- category: Neoplasia
  name: Thyroid Carcinoma
  description: >
    Thyroid neoplasms are the most frequent malignancy in WS. A possible
    genotype-phenotype correlation has been reported in Japanese patients, with
    follicular carcinoma associated with C-terminal and papillary carcinoma with
    N-terminal WRN variants, though this needs confirmation.
  phenotype_term:
    preferred_term: Thyroid carcinoma
    term:
      id: HP:0002890
      label: Thyroid carcinoma
  evidence:
  - reference: PMID:23573208
    reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ranging from 53.5-fold for melanoma of the skin (95% CI: 24.5, 101.6) to 8.9 (95% CI: 4.9, 15.0) for thyroid neoplasms"
    explanation: >-
      Gives the standardized incidence ratio for thyroid neoplasms in
      Japan-resident WS patients.
- category: Neoplasia
  name: Malignant Melanoma
  description: >
    Malignant melanoma carries the highest relative risk of any WS neoplasm, with
    a standardized incidence ratio of 53.5 in Japan-resident patients. In WS it
    characteristically arises at acral and mucosal sites rather than in
    sun-exposed skin.
  phenotype_term:
    preferred_term: Melanoma
    term:
      id: HP:0002861
      label: Melanoma
  evidence:
  - reference: PMID:23573208
    reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ranging from 53.5-fold for melanoma of the skin (95% CI: 24.5, 101.6)"
    explanation: >-
      Quantifies melanoma as the most strongly elevated neoplasm risk in WS.
- category: Neoplasia
  name: Soft Tissue Sarcoma
  description: >
    Soft tissue sarcomas are among the six neoplasms accounting for two-thirds of
    WS tumors. The sarcoma excess relative to age-matched controls is the clearest
    signal that the WS cancer spectrum is mesenchymally weighted rather than
    resembling accelerated ordinary aging.
  phenotype_term:
    preferred_term: Soft tissue sarcoma
    term:
      id: HP:0030448
      label: Soft tissue sarcoma
  evidence:
  - reference: PMID:23573208
    reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcomas, leukemia and pre-leukemic conditions of the bone marrow, and primary bone neoplasms"
    explanation: >-
      Places soft tissue sarcoma among the six defining neoplasms of the WS
      spectrum.
- category: Neoplasia
  name: Meningioma
  description: >
    Meningioma is one of the six most frequent WS neoplasms and one of the five
    for which standardized incidence is significantly elevated.
  phenotype_term:
    preferred_term: Meningioma
    term:
      id: HP:0002858
      label: Meningioma
  evidence:
  - reference: PMID:23573208
    reference_title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thyroid neoplasms, malignant melanoma, meningioma, soft tissue sarcomas, leukemia and pre-leukemic conditions of the bone marrow, and primary bone neoplasms"
    explanation: Places meningioma among the six defining neoplasms of the WS spectrum.
- category: Neoplasia
  name: Osteosarcoma
  description: >
    Osteosarcoma is specifically documented within the characteristic WS tumor
    spectrum. This narrower phenotype does not stand in for every primary bone
    neoplasm reported in the systematic review.
  phenotype_term:
    preferred_term: Osteosarcoma
    term:
      id: HP:0002669
      label: Osteosarcoma
  evidence:
  - reference: PMID:33373317
    reference_title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "comprised lung cancer, lung adenocarcinoma, undifferentiated pleomorphic sarcoma, fibrosarcoma, osteosarcoma, colorectal cancer, follicular thyroid cancer, and melanoma."
    explanation: >-
      The modern registry explicitly names osteosarcoma, so the HPO mapping and
      cited entity now have matching scope.
genetic:
- name: WRN
  gene_term:
    preferred_term: WRN
    term:
      id: hgnc:12791
      label: WRN
  association: Causative
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  notes: >
    WRN (chromosome 8p12, 34 coding exons over 140 kb) encodes the 1,432-amino
    acid, 160 kDa WRN protein. It is the only gene in which mutations cause
    classical WS, and WS is the only disorder caused by WRN null mutations.
    Nearly 100 pathogenic variants have been reported; most are nonsense, small
    indel or splicing
    variants that truncate the protein and remove the C-terminal nuclear
    localization signal, and two exonuclease-domain missense variants
    (p.Lys125Asn, p.Lys135Glu) destabilize the protein and are functionally null.
    Two helicase-domain missense alleles (p.Gly574Arg, p.Arg637Trp) abolish or are
    predicted to abolish helicase activity and produce a phenotype
    indistinguishable from null, which is the human genetic evidence that helicase
    activity is the critical WRN function.
  evidence:
  - reference: PMID:8602509
    reference_title: "Positional cloning of the Werner's syndrome gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The gene responsible for WS (known as WRN) was identified by positional cloning."
    explanation: Establishes WRN as the causal gene for Werner syndrome.
  - reference: PMID:8602509
    reference_title: "Positional cloning of the Werner's syndrome gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four mutations in WS patients were identified. Two of the mutations are splice-junction mutations"
    explanation: >-
      Documents the truncating/splicing character of the founding WRN disease
      alleles.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "It is caused by null mutations of the WRN gene, which encodes a member of the RECQ family of DNA helicases."
    explanation: >-
      Confirms that WS-associated WRN alleles act as functional nulls.
  - reference: PMID:35534204
    reference_title: Targeted long-read sequencing identifies missing pathogenic variants in unsolved Werner syndrome cases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, nearly 100 different pathogenic variants have been reported in individuals with WS worldwide."
    explanation: >-
      Updates the variant-count statement and preserves the distinction between
      molecularly diverse alleles and their predominantly functional-null effect.
diagnosis:
- name: Clinical Diagnostic Criteria (Four Cardinal Signs)
  description: >
    International Registry criteria classify a presentation as definite when all
    four cardinal signs — bilateral ocular cataracts, premature graying and/or
    thinning of scalp hair, characteristic dermatologic pathology, and short
    stature — occur with at least two additional signs. These historical clinical
    criteria are useful for recognition but do not replace molecular confirmation,
    especially before cataracts appear.
  diagnosis_term:
    preferred_term: clinical evaluation
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: >-
    Definite clinical criteria: all four cardinal signs plus at least two
    additional signs.
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of Werner syndrome can be established in a proband with clinical diagnostic criteria (presence of all four cardinal signs: bilateral ocular cataracts, premature graying and/or thinning of scalp hair, characteristic dermatologic pathology, and short stature; and two additional characteristic signs)"
    explanation: >-
      States the clinical criteria verbatim, including the requirement for two
      additional signs beyond the four cardinal ones.
- name: WRN Molecular Genetic Testing
  description: >
    Identification of biallelic WRN pathogenic variants establishes the diagnosis
    independently of the clinical criteria. This matters more than a confirmatory
    test usually does in WS, because the clinical criteria are conjunctive and
    late-completing: a proband who has not yet developed cataracts cannot meet
    them, while the genotype is available from birth. It is also what makes the
    atypical, non-WRN progeroid presentations separable from WS proper. Sequence
    analysis should be followed by deletion/duplication or genome-scale analysis
    when needed. Biallelic variants of uncertain significance, or one
    pathogenic/likely pathogenic variant plus a VUS, do not establish the
    diagnosis.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  markers: Biallelic WRN pathogenic variants
  results: >-
    Biallelic WRN pathogenic variants establish the diagnosis; identification in
    the proband also enables carrier testing of relatives and prenatal or
    preimplantation genetic testing. If a compelling phenotype yields only one
    pathogenic coding allele, targeted long-read or genome sequencing can detect
    deep-intronic and structural second alleles missed by routine analysis.
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "or biallelic WRN pathogenic variants identified by molecular genetic testing"
    explanation: >-
      States molecular confirmation as an alternative, independently sufficient
      route to the diagnosis.
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Once the WRN pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible."
    explanation: >-
      Supports the downstream family-testing options that follow from molecular
      confirmation in the proband.
  - reference: PMID:35534204
    reference_title: Targeted long-read sequencing identifies missing pathogenic variants in unsolved Werner syndrome cases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The International Registry of Werner Syndrome has identified biallelic pathogenic variants in 179/188 cases of classical WS. In the remaining nine cases, only one heterozygous pathogenic variant has been identified."
    explanation: >-
      Defines the high-yield unresolved scenario: a classic phenotype with one
      detected pathogenic WRN allele.
  - reference: PMID:35534204
    reference_title: Targeted long-read sequencing identifies missing pathogenic variants in unsolved Werner syndrome cases.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified a second pathogenic variant in eight of nine unsolved WS cases. In five cases, T-LRS identified intronic splice variants that were confirmed by either RT-PCR or exon trapping to affect splicing; in one case, T-LRS identified a 339 kbp deletion, and in two cases, pathogenic missense variants."
    explanation: >-
      Directly supports long-read escalation and shows why both noncoding splice
      variation and structural variation must be considered.
differential_diagnoses:
- name: Atypical Werner Syndrome
  description: >-
    Atypical Werner syndrome is a WRN-negative, genetically heterogeneous
    progeroid presentation rather than a subtype of classic Werner syndrome.
    Dominant LMNA and POLD1 variants are established causes within this residual
    clinical category.
  distinguishing_features:
  - Absence of biallelic pathogenic WRN variants argues against classic Werner syndrome.
  - LMNA- and POLD1-associated atypical presentations are generally dominant, unlike autosomal recessive WRN disease.
  - POLD1-related MDPL may include mandibular hypoplasia, deafness, progeroid features, and lipodystrophy.
  disease_term:
    preferred_term: atypical Werner syndrome
    term:
      id: MONDO:0019321
      label: atypical Werner syndrome
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These patients were suspected to have WS on clinical grounds, but were found on subsequent analysis to lack WRN mutations."
    explanation: >-
      Directly supports separating the WRN-negative clinical mimic from classic
      biallelic-WRN Werner syndrome.
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The POLD1 mutations found in AWS are dominant heterozygous mutations, p.Ser605del and p.Arg507Cys, which perturb polymerase activity"
    explanation: >-
      Supplies a genetically distinct dominant cause within the atypical Werner
      category.
- name: Hutchinson-Gilford Progeria Syndrome
  description: >-
    HGPS overlaps through alopecia, sclerodermatous skin, lipoatrophy, and severe
    atherosclerosis, but begins in childhood and is usually caused by a de novo
    LMNA cryptic-splice variant producing progerin. Classic WS is adolescent/adult
    onset, autosomal recessive, and WRN-related, with bilateral cataracts and its
    distinctive tumor spectrum.
  distinguishing_features:
  - Childhood onset and failure to thrive favor HGPS over adult-onset Werner syndrome.
  - A de novo LMNA exon 11 cryptic-splice variant and progerin distinguish HGPS from biallelic WRN loss.
  - Bilateral posterior subcapsular cataracts and cancer predisposition favor Werner syndrome.
  disease_term:
    preferred_term: Hutchinson-Gilford progeria syndrome
    term:
      id: MONDO:0008310
      label: Hutchinson-Gilford progeria syndrome
  evidence:
  - reference: PMID:12714972
    reference_title: Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "18 out of 20 classical cases of HGPS harboured an identical de novo (that is, newly arisen and not inherited) single-base substitution, G608G(GGC > GGT), within exon 11."
    explanation: >-
      The primary human genetic series supplies the de novo LMNA mechanism that
      separates HGPS from inherited WRN disease.
- name: Bloom Syndrome
  description: >-
    Bloom syndrome is another autosomal recessive RecQ-helicase
    cancer-predisposition disorder, but severe pre- and postnatal growth deficiency,
    photosensitivity, immune abnormalities, recurrent infections, and biallelic
    BLM variants distinguish it from adolescent-onset WS.
  distinguishing_features:
  - Severe prenatal growth deficiency and photosensitive facial erythema favor Bloom syndrome.
  - Immune deficiency and recurrent infections are characteristic of Bloom syndrome, not classic Werner syndrome.
  - Biallelic BLM variants and markedly increased sister-chromatid exchange distinguish Bloom syndrome molecularly.
  disease_term:
    preferred_term: Bloom syndrome
    term:
      id: MONDO:0008876
      label: Bloom syndrome
  evidence:
  - reference: PMID:20301572
    reference_title: Bloom Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Bloom syndrome (BSyn) is characterized by severe pre- and postnatal growth deficiency, immune abnormalities, sensitivity to sunlight, insulin resistance, and a high risk for many cancers that occur at an early age."
    explanation: >-
      GeneReviews directly states the early growth, immune, photosensitivity,
      metabolic, and cancer pattern used to distinguish Bloom syndrome.
- name: Rothmund-Thomson Syndrome
  description: >-
    Rothmund-Thomson syndrome overlaps through sparse hair, small stature,
    cataracts, and cancer predisposition. Its infantile poikiloderma, congenital
    skeletal abnormalities, and biallelic RECQL4 or ANAPC1 variants distinguish
    it from adult-onset WRN disease.
  distinguishing_features:
  - A facial rash beginning at three to six months and evolving to poikiloderma strongly favors Rothmund-Thomson syndrome.
  - Radial-ray or other congenital skeletal abnormalities favor Rothmund-Thomson syndrome.
  - Biallelic RECQL4 or ANAPC1 variants distinguish RTS from biallelic WRN-related Werner syndrome.
  disease_term:
    preferred_term: Rothmund-Thomson syndrome
    term:
      id: MONDO:0010002
      label: Rothmund-Thomson syndrome
  evidence:
  - reference: PMID:20301415
    reference_title: Rothmund-Thomson Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The rash of RTS typically develops between ages three and six months (occasionally as late as age two years) as erythema, swelling, and blistering on the face, subsequently spreading to the buttocks and extremities."
    explanation: >-
      The infantile rash timing sharply separates RTS from the post-pubertal
      onset of Werner syndrome.
treatments:
- name: Nicotinamide Riboside (EMPOWER Early-Phase Trial)
  description: >-
    Oral nicotinamide riboside (NR) 1000 mg daily was evaluated in a phase I/II
    double-blind randomized crossover study (26 weeks per arm). Eleven patients
    enrolled, nine were randomized, and six completed. No serious adverse events
    were reported during NR treatment; CAVI and ulcer-area signals favored NR.
    Interpretation is limited by the single-center sample, dropouts, no washout,
    and ulcer analysis in only three patients (all received NR first). Right ABI
    worsened statistically, and blood pressure, sarcopenia, lipid, glucose, and
    kidney-function markers did not differ significantly. NR is therefore an
    investigational option with early human evidence, not established
    disease-modifying care.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Skin ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  - preferred_term: Atherosclerosis
    term:
      id: HP:0002621
      label: Atherosclerosis
  target_mechanisms:
  - target: NAD+ Depletion
    treatment_effect: RESTORES
    description: NR supplementation increased plasma NAD+ in the human crossover trial.
    evidence:
    - reference: PMID:40459998
      reference_title: "Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "As expected, NAD+ levels increased significantly following NR treatment"
      explanation: >-
        The pharmacodynamic measurement directly supports restoration of the
        depleted NAD+ pool, without proving correction of WRN itself.
  evidence:
  - reference: PMID:40459998
    reference_title: "Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No serious adverse events were observed during NR treatment. Importantly, CAVI improved, the skin ulcer area decreased, and heel pad thinning showed a declining trend."
    explanation: >-
      The randomized crossover report supplies the main safety and secondary
      endpoint signals.
  - reference: PMID:40459998
    reference_title: "Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No significant differences were observed between the NR and placebo phases in regard to changes from baseline regarding blood pressure; sarcopenia indicators, lipid metabolism parameters, glucose metabolism markers, and kidney function markers."
    explanation: >-
      Negative secondary endpoints prevent a broad efficacy or renal-protection
      claim.
  - reference: PMID:40459998
    reference_title: "Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study had some limitations. First, the number of patients was small because this was a single‐center study, which coincided with the COVID‐19 pandemic."
    explanation: >-
      The authors' limitation statement supports cautious interpretation.
- name: WRN-108 Genotype-Restricted Exon-Skipping ASO
  action_category: THERAPEUTIC
  therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
  aso_details:
    aso_mechanism: SPLICE_MODULATION_EXON_SKIPPING
    target_gene:
      preferred_term: WRN
      term:
        id: hgnc:12791
        label: WRN
    target_transcript: WRN pre-mRNA carrying biallelic c.3139-1G>C
    target_exon: exon 27
    aso_chemistry: TWO_PRIME_O_METHOXYETHYL
    conjugation: UNCONJUGATED
  description: >-
    WRN-108 is a fully phosphorothioate, uniformly 2'-MOE splice-switching ASO
    designed for the c.3139-1G>C subgroup. In patient fibroblasts it induces exon
    27 skipping after pathogenic exon 26 skipping, restores an in-frame transcript,
    and re-establishes partial WRN protein expression and nuclear localization.
    Rat wounds established dermal pharmacokinetics; one cynomolgus monkey showed
    skin target engagement, and short mouse/minipig studies addressed tolerability.
    No model combined the human splice genotype with a WS chronic-ulcer phenotype,
    no wound-healing efficacy endpoint was tested, and long-term safety is unknown.
    Wild-type exon 27 skipping could reduce WRN expression. This is a
    genotype-restricted preclinical candidate, not clinical care.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Skin ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  target_mechanisms:
  - target: c.3139-1G>C-Dependent WRN Pre-mRNA Missplicing
    treatment_effect: BYPASSES
    description: >-
      WRN-108 causes additional exon 27 skipping to restore the open reading
      frame disrupted by c.3139-1G>C-dependent exon 26 skipping.
    evidence:
    - reference: PMID:42095135
      reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "subsequent DNA sequencing confirmed exon 25–28 junction formation"
      explanation: >-
        The induced junction directly demonstrates bypass of the pathogenic
        frameshift-producing splice state.
  evidence:
  - reference: PMID:42095135
    reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In WS patient-derived fibroblasts, WRN-108 efficiently induced exon 27 skipping, restored WRN protein expression, and re-established its nuclear localization."
    explanation: >-
      Direct patient-cell evidence establishes the intended molecular effect.
  - reference: PMID:42095135
    reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Although this evaluation was limited to a single animal, the detection of exon-skipped transcripts supports pharmacodynamic activity within treated tissue."
    explanation: >-
      The single primate establishes local target engagement only, not efficacy
      or general safety.
- name: Bosentan for Lower-Extremity Ulcers
  description: >
    Bosentan is a dual endothelin-receptor antagonist used for refractory
    lower-extremity ulcers in WS. GeneReviews recommends it on the basis of very
    limited disease-specific evidence, including case-level experience, rather
    than a controlled WS trial. It treats a manifestation, not the WRN defect,
    and should not be presented as established ulcer-healing efficacy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bosentan
      term:
        id: CHEBI:51450
        label: bosentan
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Targeted therapy: Bosentan reduces vasoconstriction to improve healing of lower-extremity ulcers."
    explanation: >-
      GeneReviews lists bosentan as the targeted therapy for WS lower-extremity
      ulcers and states its vasodilatory mechanism.
- name: Genetic Counseling
  description: >
    WS is autosomal recessive, so counseling of an affected proband's family turns
    on sib recurrence risk and on the testing options that molecular confirmation
    unlocks. Because sibs of a proband are themselves at 25% risk and WS is
    diagnosed late, GeneReviews additionally recommends evaluating apparently
    asymptomatic older and younger sibs, so that surveillance and preventive
    measures start before manifestations accumulate.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier"
    explanation: >-
      Gives the autosomal recessive recurrence risks that are the substance of
      counseling for this disorder.
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Evaluate apparently asymptomatic older and younger sibs of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures."
    explanation: >-
      Supports the at-risk-relative evaluation recommendation, which is
      counseling-initiated rather than proband-directed care.
- name: Risk-Factor Avoidance
  description: >
    Avoidance recommendations in WS are not generic lifestyle advice: they are
    targeted at the specific acquired diseases that kill WS patients or cause the
    signature morbidity. Smoking and obesity are avoided for atherosclerosis
    (myocardial infarction being one of the two leading causes of death); smoking
    and alcohol for osteoporosis and cataracts, both of which arrive decades
    early; and falls, extremity trauma and excessive sun exposure because
    extremity trauma can worsen vulnerable skin and chronic ulcers.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
  evidence:
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Avoid smoking and obesity, which increase the risk for atherosclerosis. Avoid smoking and alcohol, which increase the risk of osteoporosis and cataracts. Avoid falls, trauma to the extremities, and excessive sun exposure."
    explanation: >-
      States the agents and circumstances to avoid, each tied to the WS
      complication it accelerates.
- name: Cataract Surgery
  description: >
    Extraction of the bilateral posterior subcapsular cataracts, typically
    required around age 31. It is the single most consistently needed
    intervention in WS.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:26993153
    reference_title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Bilateral cataracts requiring surgery are seen in virtually all cases by the late 20s or early 30s"
    explanation: >-
      Establishes cataract surgery as a near-universal requirement in WS.
- name: Cancer Surveillance and Complication-Directed Management
  description: >
    There is no curative or disease-modifying therapy. Management consists of
    treating manifestations, preventing secondary complications, and screening for
    the acquired diseases common in WS — in practice, surveillance weighted toward
    the six neoplasms that dominate the WS spectrum. Cancer treatment should be
    individualized with close hematologic and renal monitoring rather than a
    categorical, unsupported claim that every cytotoxic regimen requires
    modification. Creatinine-based kidney indices can be biased by small body size
    and sarcopenia, so BSA-uncorrected eGFR or cystatin-C estimates may be important
    for drug dosing.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:7712642
    reference_title: "Werner's syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Patients should have a thorough clinical and laboratory work-up, keeping in mind their elevated risk for neoplasms."
    explanation: >-
      Supports neoplasm-directed surveillance as the core of WS clinical
      management.
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Annual surveillance includes ophthalmologic examination for cataracts; dual-energy x-ray absorptiometry to assess bone density; assessment for signs/symptoms of hypogonadism; fasting glucose level, hemoglobin A1c, or oral glucose tolerance test"
    explanation: >-
      Specifies the annual surveillance schedule, which is broader than the
      neoplasm-directed work-up and is keyed to the WS complication set.
  - reference: PMID:20301687
    reference_title: Werner Syndrome.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "skin examination for ulcers and lentiginous melanoma; ten-year atherosclerotic cardiovascular disease risk estimation, lipid profile, blood pressure, lifestyle counseling, and assessment for cardiovascular risk factors"
    explanation: >-
      Completes the annual schedule with the dermatologic and cardiovascular
      arms, the latter matching myocardial infarction as a leading cause of
      death in WS.
  - reference: PMID:37130431
    reference_title: Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the mean estimated glomerular filtration rate calculated from serum creatinine (eGFRcre) and eGFRcys, which were calculated from cystatin C in the first year, were 98.3 and 83.2 mL/min/1.73 m2, respectively, and differed depending on the index used."
    explanation: >-
      The current registry demonstrates index discordance relevant to medication
      dosing and surveillance in small, sarcopenic patients.
  - reference: PMID:37130431
    reference_title: Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome Registry.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In longitudinal analysis, the average eGFRcre for the first and fourth years was 74.8 and 63.4 mL/min/1.73 m2, showing a rapid decline."
    explanation: >-
      Supports longitudinal renal monitoring while the description preserves the
      creatinine/sarcopenia measurement caveat.
experimental_models:
- name: Werner Syndrome iPSC-Derived Macrophage-Vascular Co-Culture
  experimental_model_type: CO_CULTURE
  description: >-
    Two-dimensional co-culture of macrophages, vascular endothelial cells, and
    vascular smooth-muscle cells differentiated from healthy, WS, and
    gene-corrected WS iPSCs. The isogenic correction and cross-co-cultures localize
    the inflammatory driver to WS macrophages. The system models cell-cell
    interactions but lacks blood flow, vessel architecture, systemic immunity,
    and longitudinal plaque development.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: macrophage
  - preferred_term: vascular endothelial cell
  - preferred_term: vascular smooth muscle cell
  cell_source: Patient-derived and healthy-control iPSCs, plus CRISPR-corrected WS iPSCs
  culture_system: Two-dimensional macrophage-endothelial and macrophage-smooth-muscle co-culture
  conditions:
  - WRN-deficient Werner syndrome
  - healthy control
  - gene-corrected isogenic Werner syndrome control
  - oxidized LDL stimulation
  publication: PMID:38858384
  modeled_mechanisms:
  - target: Retrotransposon-Derived dsRNA Accumulation in WS Macrophages
    description: >-
      RNA-seq, ATAC-seq, chromatin profiling, and gene correction assay the
      retrotransposon/RNA-sensing arm in WS macrophages.
    evidence:
    - reference: PMID:38858384
      reference_title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "RNA-sequencing (seq) and assay for transposase-accessible chromatin using sequencing (ATAC-seq) reveal accelerated type I IFN signaling and reduced chromatin accessibility in WS-iMφs."
      explanation: >-
        Multi-omic profiling directly supports the modeled macrophage state.
  - target: DHX58-Dependent Type I Interferon Inflammation
    description: >-
      Interferon silencing and vascular co-culture assay the causal inflammatory
      step and its endothelial/smooth-muscle consequences.
    evidence:
    - reference: PMID:38858384
      reference_title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Silencing type I IFN signaling rescues proliferation and suppresses senescence and inflammation, suggesting atherosclerosis treatment in WS."
      explanation: >-
        Pathway perturbation supports the causal role in this model while not
        implying clinical treatment efficacy.
  evidence:
  - reference: PMID:38858384
    reference_title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In this work, we generate, characterize, validate, and use immune and vascular cells differentiated from iPSCs from healthy individuals and WS patients, as well as gene-corrected iPSCs from WS patients, and establish an in vitro model to better understand the atherosclerosis microenvironment at the molecular level."
    explanation: >-
      Defines the patient/control/gene-corrected composition and intended use of
      the non-animal model.
- name: c.3139-1G>C Werner Fibroblast WRN-108 Rescue Model
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: >-
    Dermal fibroblasts from a person homozygous for WRN c.3139-1G>C, compared with
    healthy fibroblasts and a non-targeting ASO, test genotype-matched WRN-108
    uptake, splice correction, protein localization, proliferation, senescence,
    G-quadruplex, and γH2AX readouts. This cellular model cannot establish chronic
    ulcer healing or systemic efficacy.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: skin fibroblast
    term:
      id: CL:0002620
      label: skin fibroblast
  cell_source: Patient-derived dermal fibroblasts (Coriell AG12795) and healthy control fibroblasts
  culture_system: Primary fibroblast monolayer with transfection-free WRN-108 exposure
  conditions:
  - homozygous WRN c.3139-1G>C
  - WRN-108 treatment
  - vehicle and non-targeting ASO controls
  publication: PMID:42095135
  modeled_mechanisms:
  - target: WRN-108-Directed Exon 27 Skipping
    description: Measures the exon 25-exon 28 splice junction after WRN-108 exposure.
    evidence:
    - reference: PMID:42095135
      reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "subsequent DNA sequencing confirmed exon 25–28 junction formation"
      explanation: Direct junction sequencing validates the modeled splice-effector state.
  - target: Restored Partial WRN Expression and Nuclear Localization
    description: Measures WRN protein abundance/localization and downstream genome-maintenance readouts.
    evidence:
    - reference: PMID:42095135
      reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Treatment improved cell proliferation and reduced senescence-associated markers, G-quadruplex accumulation, and γH2AX signaling, consistent with partial restoration of WRN-dependent genome maintenance functions."
      explanation: >-
        Functional cellular rescue supports partial WRN restoration while not
        substituting for a wound-healing endpoint.
  evidence:
  - reference: PMID:42095135
    reference_title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In WS patient-derived fibroblasts, WRN-108 efficiently induced exon 27 skipping, restored WRN protein expression, and re-established its nuclear localization."
    explanation: Directly defines the model, intervention, and primary molecular outputs.
datasets:
- accession: geo:GSE247722
  title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model
  description: >-
    GEO superseries for the WS iPSC-derived macrophage/endothelial/vascular
    smooth-muscle study, integrating RNA-seq, ATAC-seq, and chromatin profiling
    across patient, healthy-control, and gene-corrected cells.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MULTI_OMICS
  sample_count: 97
  conditions:
  - Werner syndrome iPSC-derived macrophages and vascular cells
  - healthy controls
  - gene-corrected Werner syndrome controls
  publication: PMID:38858384
  evidence:
  - reference: PMID:38858384
    reference_title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "RNA-sequencing (seq) and assay for transposase-accessible chromatin using sequencing (ATAC-seq) reveal accelerated type I IFN signaling and reduced chromatin accessibility in WS-iMφs."
    explanation: >-
      The publication describes the core omics assays represented by the
      superseries.
  notes: >-
    Identified by GEO discovery and verified against NCBI E-utilities on
    2026-08-24; GEO reports Homo sapiens, 97 samples, and PMID:38858384.
clinical_trials:
- name: jRCTs031190141
  phase: PHASE_II
  status: COMPLETED
  description: >-
    EMPOWER was a combined phase I/II, double-blind, randomized,
    placebo-controlled crossover trial of oral nicotinamide riboside 1000 mg daily for
    26 weeks per arm in Werner syndrome. The registry target was 30; eleven
    enrolled, nine were randomized, and six completed in the publication. The
    schema lacks a combined phase-I/II value, so PHASE_II records the later phase
    while this description preserves the registry's exact phase 1-2 designation.
  target_phenotypes:
  - preferred_term: Skin ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  - preferred_term: Atherosclerosis
    term:
      id: HP:0002621
      label: Atherosclerosis
  evidence:
  - reference: ICTRP:JPRN-jRCTs031190141
    reference_title: Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| Study design | randomized controlled trial, double blind, placebo control, crossover assignment, treatment purpose |"
    explanation: The sanctioned WHO ICTRP cache supplies the structured trial design.
  - reference: ICTRP:JPRN-jRCTs031190141
    reference_title: Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| Recruitment status | Complete |"
    explanation: The registry record establishes completed status.
  - reference: ICTRP:JPRN-jRCTs031190141
    reference_title: Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| Phase | 1-2 |"
    explanation: >-
      Preserves the registry's combined phase designation despite the local
      single-value phase enum.
  - reference: PMID:40459998
    reference_title: "Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eleven patients with WS were enrolled in the study, and nine were randomized"
    explanation: >-
      The results publication supplies actual enrollment and randomization,
      complementing the registry's planned target.
animal_models:
- name: Telomere-limited Wrn-null mouse (mTerc-/- Wrn-/-)
  species: Mouse
  genotype: Wrn-/- Terc-/- (late generation)
  publication: PMID:15235603
  description: >
    Wrn-null mice on a telomerase-proficient background are essentially
    unaffected, which for years made WS look untranslatable to the mouse. Crossing
    Wrn deficiency onto a Terc-null background and breeding to late generations
    exhausts the mouse's long telomere reserve and unmasks a Werner-like syndrome.
    The model demonstrates that telomere reserve is rate-limiting in this
    engineered mouse background; it does not by itself establish telomere
    attrition as the primary human organismal trigger.
  modeled_mechanisms:
  - target: Telomere Maintenance Failure
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >
      Late-generation double-null mice demonstrate that telomere exhaustion can
      precipitate a Werner-like phenotype from Wrn loss in this engineered model.
    limitations: >-
      The requirement for an engineered telomerase-null background is itself a
      species difference: laboratory mice have telomeres far longer than humans,
      so the model reconstructs a human baseline rather than reproducing one.
      Conclusions about the ordering of events transfer better than conclusions
      about rates.
    evidence:
    - reference: PMID:15235603
      reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the lack of a disease phenotype in Wrn-deficient mice with long telomeres implicate telomere attrition in the pathogenesis of Werner syndrome"
      explanation: >-
        States the negative result in long-telomere Wrn-null mice that motivates
        the telomere-limited cross.
  - target: Segmental Progeroid Tissue Failure
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >
      The double-null mice develop premature death, hair graying, alopecia,
      osteoporosis, type II diabetes and cataracts.
    limitations: >-
      Recapitulation is of the progeroid features as a set; the model has not been
      shown to reproduce the specifically WS-discordant distribution
      (distal-predominant osteoporosis, posterior subcapsular rather than
      nuclear cataract) that distinguishes WS from ordinary aging in humans.
    readouts:
    - name: Werner-like premature aging phenotype
      target: Segmental Progeroid Tissue Failure
      direction: INCREASED
      interpretation: >-
        Appearance of the progeroid feature set in late-generation double-null
        mice but not in Wrn-null mice with long telomeres.
      evidence:
      - reference: PMID:15235603
        reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "telomere dysfunction elicits a classical Werner-like premature aging syndrome typified by premature death, hair graying, alopecia, osteoporosis, type II diabetes and cataracts"
        explanation: Reports the specific progeroid features scored in the model.
    evidence:
    - reference: PMID:15235603
      reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In late-generation mice null with respect to both Wrn and Terc (encoding the telomerase RNA component)"
      explanation: >-
        Defines the genotype and generation requirement for the model to be
        informative.
- name: Wrn-null mouse on a telomerase-proficient background
  species: Mouse
  genotype: Wrn-/-
  publication: PMID:15235603
  description: >
    The simple Wrn knockout, which does not develop an overt progeroid phenotype.
    Recorded here as an explicit negative result rather than omitted, because the
    absence of a phenotype is itself the informative finding.
  modeled_mechanisms:
  - target: Segmental Progeroid Tissue Failure
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >
      Wrn deficiency alone does not produce a Werner-like syndrome in mice with
      long telomeres.
    limitations: >-
      The failure is attributable to the mouse's long telomere reserve rather than
      to WRN having a different function in mice, so this model should not be
      cited as evidence against a WRN-centred mechanism in humans — only against a
      telomere-independent one.
    evidence:
    - reference: PMID:15235603
      reference_title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the lack of a disease phenotype in Wrn-deficient mice with long telomeres"
      explanation: >-
        Directly reports the absence of a disease phenotype in the single-null
        model.
discussions:
- discussion_id: mismatch_wrn_mouse_telomere_reserve
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Does the requirement for a telomerase-null background in the mouse mean that
    telomere attrition is the true rate-limiting step in human WS, or only that
    mice need their telomere advantage removed before any WRN-dependent
    phenotype can be seen?
  attaches_to:
  - pathophysiology#Telomere Maintenance Failure
  - pathophysiology#Segmental Progeroid Tissue Failure
  rationale: >
    Wrn-null mice with long telomeres are phenotypically normal, and a Werner-like
    syndrome appears only in late-generation mTerc-/- Wrn-/- animals. Two readings
    are compatible with this. Under the first, telomere attrition is genuinely the
    rate-limiting step and the mouse cross simply restores a human-like telomere
    baseline; the hTERT rescue of WS patient fibroblasts supports this. Under the
    second, the mouse has redundant RecQ or telomere-protection capacity that
    humans lack, and the telomerase-null background unmasks a phenotype whose
    human rate-limiting step is elsewhere — for instance in replication fork
    recovery at non-telomeric loci, which the mouse experiments did not assess.
    The two readings diverge on whether telomere-directed intervention would be
    disease-modifying in patients, so the distinction is not academic. Note also
    that the Wrn helicase-domain-deletion mouse has a mild phenotype and a
    10-15% shorter median lifespan where the full null does not, raising the
    separate possibility of a dominant-negative contribution from
    helicase-dead protein that a pure loss-of-function model cannot capture.
  proposed_experiments:
  - experiment_id: exp_ws_htert_nontelomeric_damage_burden
    name: Non-telomeric damage burden in hTERT-rescued WS fibroblasts
    description: >
      hTERT immortalization abolishes the proliferative defect of WS fibroblasts,
      but whether it also normalizes damage accumulation at non-telomeric DNA has
      not been assessed. Quantifying genome-wide damage foci, common fragile site
      expression and replication fork progression in matched WS and WS-hTERT
      fibroblasts would separate the two readings: full normalization supports
      telomeres as rate-limiting, while a persisting non-telomeric defect implies
      the mouse cross unmasks rather than reproduces the human mechanism.
- discussion_id: gap_ws_mesenchymal_tumor_spectrum
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why is the WS neoplasm spectrum mesenchymally weighted rather than resembling
    the epithelial-dominated cancer spectrum of ordinary aging?
  attaches_to:
  - pathophysiology#Cancer Predisposition with Mesenchymal Weighting
  rationale: >
    If WS were simply accelerated aging, its tumor spectrum should be a
    time-shifted version of the general-population spectrum. It is not: sarcomas,
    melanoma, meningioma and thyroid neoplasms dominate, with standardized
    incidence ratios up to 53.5-fold. Two non-exclusive explanations are current —
    differential WRN dependence across lineages and cell-turnover rates, and the
    preferential use by sarcomas of the recombination-based ALT telomere
    maintenance pathway that WRN normally suppresses. Neither has been tested in a
    way that would apportion the effect, and the discrepancy is a standing
    argument against reading WS as a general model of aging.
- discussion_id: gap_nr_empower_replication
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Do the vascular-stiffness and skin-ulcer signals from EMPOWER replicate in a
    larger parallel-group trial with washout-independent clinical endpoints?
  attaches_to:
  - treatments#Nicotinamide Riboside (EMPOWER Early-Phase Trial)
  - clinical_trials#jRCTs031190141
  rationale: >-
    EMPOWER provides randomized, double-blind crossover evidence, but only nine
    participants were randomized and six completed. There was no washout, all
    three participants contributing ulcer measurements received NR first, the
    right ankle-brachial index worsened statistically, and prespecified metabolic,
    sarcopenia, blood-pressure, and kidney-function markers did not improve. A
    larger trial should prioritize durable ulcer healing, validated vascular and
    patient-reported endpoints, sufficient washout, and an analysis robust to
    dropout before NR is regarded as disease-modifying care.
  proposed_experiments:
  - experiment_id: exp_ws_nr_parallel_replication
    name: Multicenter parallel-group NR replication trial
    description: >-
      Randomize a multicenter molecularly confirmed WS cohort to NR or placebo
      with blinded ulcer adjudication, prespecified vascular endpoints, adequate
      follow-up, and pharmacodynamic NAD+ measurements.
- discussion_id: gap_wrn108_translational_model
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Can genotype-restricted WRN-108 produce durable chronic-ulcer healing without
    unacceptable long-term on-target or off-target toxicity?
  attaches_to:
  - treatments#WRN-108 Genotype-Restricted Exon-Skipping ASO
  - experimental_models#c.3139-1G>C Werner Fibroblast WRN-108 Rescue Model
  rationale: >-
    WRN-108 restores an in-frame WRN transcript, partial protein expression, and
    nuclear localization in c.3139-1G>C patient fibroblasts. The animal work
    establishes dermal exposure and, in one primate, local exon skipping, but no
    model combines the human splice allele with a WS chronic-ulcer phenotype and
    no wound-healing efficacy endpoint was tested. The candidate is restricted to
    a defined splice-genotype subgroup; chronic dosing, wild-type transcript
    effects, and systemic safety remain unresolved.
  proposed_experiments:
  - experiment_id: exp_wrn108_humanized_ulcer_model
    name: Humanized c.3139-1G>C chronic-ulcer efficacy and safety study
    description: >-
      Test repeated dermal dosing in a model carrying the human target sequence
      and a reproducible WS-like wound phenotype, with healing, biodistribution,
      wild-type splice, immunogenicity, and long-term toxicology readouts.
- discussion_id: gap_rte_ifn_patient_vessel_validation
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does macrophage RTE-dsRNA–DHX58–type-I-interferon signaling drive vascular
    disease in patient vessels and in vivo, beyond the iPSC co-culture system?
  attaches_to:
  - pathophysiology#Retrotransposon-Derived dsRNA Accumulation in WS Macrophages
  - pathophysiology#DHX58-Dependent Type I Interferon Inflammation
  - experimental_models#Werner Syndrome iPSC-Derived Macrophage-Vascular Co-Culture
  rationale: >-
    Patient, control, and gene-corrected iPSC-derived cells plus pathway silencing
    support a causal chain within the co-culture. Whether the same macrophage
    state exists in human arterial lesions, precedes clinical atherosclerosis, or
    can be inhibited without impairing host defense has not been established.
  proposed_experiments:
  - experiment_id: exp_ws_vessel_rte_ifn_validation
    name: Spatial validation of RTE–IFN signaling in WS vessels
    description: >-
      Combine spatial transcriptomics and dsRNA/IFN-pathway imaging in WS vascular
      tissue with lineage-resolved perturbation in an in vivo or vascular-organoid
      model.
- discussion_id: gap_ws_renal_trajectory_measurement
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    How much of the longitudinal creatinine-based eGFR decline in WS represents
    renal injury rather than bias from low muscle mass and body-size indexing?
  attaches_to:
  - phenotypes#Decreased Muscle Mass and Sarcopenic Physique
  - treatments#Cancer Surveillance and Complication-Directed Management
  rationale: >-
    The registry observed declining creatinine-based eGFR, but WS combines short
    stature, limb lipoatrophy, and sarcopenia, making creatinine production and
    body-surface-area normalization unusually problematic. Cystatin-C and
    unindexed estimates can disagree with standard eGFR; resolving the true renal
    trajectory matters for surveillance and drug dosing.
  proposed_experiments:
  - experiment_id: exp_ws_measured_gfr_longitudinal
    name: Longitudinal measured-GFR and body-composition cohort
    description: >-
      Compare measured GFR, creatinine, cystatin C, unindexed estimates, albuminuria,
      imaging, and quantitative muscle mass longitudinally in molecularly confirmed
      WS.
notes: >
  Scope and framing caveats a curator should preserve:

  Segmental, not global. WS is routinely described as "accelerated aging", and
  the entry uses that framing because the literature does, but the phenotype is
  explicitly segmental. Alzheimer-type dementia and increased amyloid deposition
  are not features of WS; osteoporosis is distal-predominant rather than
  vertebral; cataracts are posterior subcapsular rather than nuclear; and the
  cancer spectrum is mesenchymal rather than epithelial. Intellectual disability,
  dysmorphology and skeletal anomalies are not WS features and, when present, are
  attributed to co-existing disorders. Any downstream use of this entry as an
  aging model should carry these discordances with it.

  Atypical Werner syndrome is a distinct entity with its own MONDO class,
  MONDO:0019321, defined by the ABSENCE of a WRN lesion in a clinically
  WS-like patient. It is genetically heterogeneous — LMNA is the best-known but
  not the only arm — so it cannot be a has_subtypes entry here: a residual
  category defined by not having this disease's causal lesion shares only a
  clinical gestalt with it, not a proximal mechanism. It is recorded as a
  differential rather than folded in; LMNA-related cases overlap the existing
  laminopathy neighbourhood (Hutchinson-Gilford_Progeria_Syndrome). Confirmation
  of a classical WS diagnosis requires WRN gene testing.

  Module wiring: this entry conforms to the AGING-facing genomic_instability_aging
  module, not the cancer-facing genome_instability_mutation module. That module's
  own notes name Werner among its natural conformers and say explicitly not to
  duplicate the cancer arm there. Xeroderma_Pigmentosum is the closest structural
  precedent — likewise a DNA-repair-deficiency disorder with cancer predisposition
  that wires its core chain to the aging arm. Similarly, the telomere node attaches
  to telomere_attrition (maintenance FAILURE) and deliberately not to the
  hallmark-of-cancer module enabling_replicative_immortality, which models
  telomere-maintenance REACTIVATION — the opposite direction; wiring both would
  assert two contradictory things about the same biology.

  Module expansion is evidence-scoped. The mitochondrial/mitophagy and
  adipose-stem-cell arms are now represented by evidenced nodes, as are the
  macrophage retrotransposon–interferon and SHOX-G-quadruplex mechanisms. Broader
  claims about a global epigenetic clock or organism-wide stem-cell exhaustion
  remain outside the curated graph. The macrophage heterochromatin signal is
  encoded only as the experimentally tested RTE-dsRNA arm, not generalized to all
  tissues.

  The genotype-restricted WRN-108 chain conforms to the antisense-oligonucleotide
  splice-redirection module because its trigger, splice-effector state, and
  restored transcript/protein state are all explicitly curated. That module edge
  does not imply clinical efficacy; the evidence remains cellular, dermal-PK, and
  single-animal target engagement.

  Causal phenotype connectivity is deliberately partial. Registry frequency
  establishes that scleroderma-like skin change, soft-tissue calcification,
  truncal adiposity, characteristic facies and voice, ulcers, sarcopenia,
  dyslipidemia, steatosis, hypertension, and hypogonadism occur in WS; it does not
  establish their proximate routes from WRN loss. Those manifestations remain
  unwired rather than being forced through the broad segmental-tissue-failure
  node. Cancer phenotypes are wired only from genomic-instability-driven cancer
  predisposition, never from tissue failure.

  RecQ siblings. WS completes the RecQ-helicase triad already partly in the KB
  alongside Bloom_Syndrome (BLM) and Rothmund-Thomson_Syndrome (RECQL4).

  The WRN mouse discordance is recorded as a HUMAN_MODEL_MISMATCH above rather
  than being resolved in the pathograph.

  Reverse-direction relevance to oncology. WRN helicase activity — the function
  lost in WS — is a synthetic lethal dependency in microsatellite-unstable
  cancers, where WRN depletion induces double-strand breaks, apoptosis and cell
  cycle arrest while sparing microsatellite-stable models. Notably the dependency
  requires the helicase but not the exonuclease activity, mirroring the human
  genetics in which helicase-dead missense alleles produce a full WS phenotype.
  This is not a treatment for WS and is deliberately not curated in treatments:
  it is sporadic-cancer pharmacology that happens to target the WS gene, and
  conflating the two would imply WRN inhibition is therapeutic in a disease
  caused by WRN loss. See PMID:30971823.
references:
- reference: PMID:20301687
  title: Werner Syndrome.
  tags:
  - GeneReviews
- reference: PMID:8602509
  title: "Positional cloning of the Werner's syndrome gene."
- reference: PMID:26993153
  title: "Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions."
- reference: PMID:23573208
  title: "Spectrum and risk of neoplasia in Werner syndrome: a systematic review."
- reference: PMID:15235603
  title: "Essential role of limiting telomeres in the pathogenesis of Werner syndrome."
- reference: PMID:7712642
  title: "Werner's syndrome."
- reference: PMID:903377
  title: "A retarded rate of DNA replication and normal level of DNA repair in Werner's syndrome fibroblasts in culture."
- reference: PMID:30971823
  title: "WRN helicase is a synthetic lethal target in microsatellite unstable cancers."
- reference: PMID:12714972
  title: Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome.
- reference: PMID:16673358
  title: The spectrum of WRN mutations in Werner syndrome patients.
- reference: PMID:20301415
  title: Rothmund-Thomson Syndrome.
  tags:
  - GeneReviews
- reference: PMID:20301572
  title: Bloom Syndrome.
  tags:
  - GeneReviews
- reference: PMID:31754102
  title: NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome.
- reference: PMID:33373317
  title: "Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan."
- reference: PMID:35534204
  title: Targeted long-read sequencing identifies missing pathogenic variants in unsolved Werner syndrome cases.
- reference: PMID:36114168
  title: WRN promotes bone development and growth by unwinding SHOX-G-quadruplexes via its helicase activity in Werner Syndrome.
- reference: PMID:37130431
  title: Renal dysfunction, malignant neoplasms, atherosclerotic cardiovascular diseases, and sarcopenia as key outcomes observed in a three-year follow-up study using the Werner Syndrome Registry.
- reference: PMID:37793000
  title: Senescence-associated inflammation and inhibition of adipogenesis in subcutaneous fat in Werner syndrome.
- reference: PMID:38858384
  title: Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model.
- reference: PMID:40459998
  title: "Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial."
- reference: PMID:42095135
  title: Development of an exon 27-skipping antisense oligonucleotide as a targeted therapy for refractory skin ulcers in Werner syndrome.
- reference: ICTRP:JPRN-jRCTs031190141
  title: Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome

📚

References & Deep Research